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Prolonging function of the corpus luteum (CL) is a method of suppressing estrus 
that maintains secretion of endogenous progesterone to keep mares out of heat naturally.  
The use of oxytocin to prolong CL function is becoming more popular. In these therapies, 
upregulation of cyclooxygenase-2 is inhibited, which impairs prostaglandin F2α (PGF2α) 
production. Intramuscular (IM) administration of 60 IU of oxytocin once daily from 7 to 
14 days after ovulation is currently the most common treatment protocol.  Although that 
protocol is efficacious in ≥70% of treated mares, the need for daily administration is a 
drawback to its use. A proprietary slow-release oxytocin formulation (SR-OT) with a 
two-injection protocol to prolong CL function was evaluated in the first experiment.  
Mares were examined to determine the day of ovulation (day 0) and then randomly 
assigned either to a non-treated control group or an SR-OT treatment group (n = 8 
mares/group).  Mares in the treated group received 1.0 mL of SR-OT containing 2,400 IU 
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oxytocin IM once on Day 7 and again on Day 10 after ovulation.  Jugular blood samples 
were collected on day 0 and then every M, W, and F through day 50. Serum progesterone 
concentrations were evaluated to assess CL function, which was prolonged in 0/8 (0%) 
control mares and 6/8 (75%) of the SR-OT treated mares (p < 0.01).  In a second study, 
the ability of the endometrium to synthesize PGF2α was evaluated in mares in a state of 
prolonged CL function. Mares were designated into groups 50-59, 60-69, or 70-79 days 
post-ovulation (50s, 60s, 70s) and 14-day post-ovulation controls. PGF2α synthesis was 
evaluated by measurement of PGFM in response to a single 10 IU intravenous oxytocin 
bolus (0 minutes). Blood samples were collected serially from 30 minutes before until 
120 minutes after oxytocin administration. The PGFM response was significantly higher 
in the 70s versus the 50s and 70s versus the 60s groups (p < 0.001; p < 0.02, 
respectively); and there was no significant difference between the 70s group and the 
control group (p > 0.36). Luteal function was maintained after oxytocin administration in 
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Prolonging function of the corpus luteum (CL) is a method of suppressing estrus 
that maintains secretion of endogenous progesterone to keep mares out of heat naturally.  
The use of oxytocin to prolong CL function is becoming more popular. In these therapies, 
upregulation of cyclooxygenase-2 is inhibited, which impairs prostaglandin F2α (PGF2α) 
production. Intramuscular (IM) administration of 60 IU of oxytocin once daily from 7 to 
14 days after ovulation is currently the most common treatment protocol.  Although that 
protocol is efficacious in ≥70% of treated mares, the need for daily administration is a 
drawback to its use. A proprietary slow-release oxytocin formulation (SR-OT) with a 
two-injection protocol to prolong CL function was evaluated in the first experiment.  
Mares were examined to determine the day of ovulation (day 0) and then randomly 
assigned either to a non-treated control group or an SR-OT treatment group (n = 8 
mares/group).  Mares in the treated group received 1.0 mL of SR-OT containing 2,400 IU 
oxytocin IM once on Day 7 and again on Day 10 after ovulation.  Jugular blood samples 
were collected on day 0 and then every M, W, and F continuously. Serum progesterone 
concentrations were evaluated to assess CL function, which was prolonged in 0/8 (0%) 
control mares and 6/8 (75%) of the SR-OT treated mares (p< 0.01).  In a second study, 
the ability of the endometrium to synthesize PGF2α was evaluated in mares in a state of 
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prolonged CL function. Mares were designated into groups 50-59, 60-69, or 70-79 days 
post-ovulation (50s, 60s, 70s) and 14-day post-ovulation controls. PGF2α synthesis was 
evaluated by measurement of a prostaglandin metabolite in response to a single 10 IU 
intravenous oxytocin bolus (0 minutes). Blood samples were collected serially from 30 
minutes before until 120 minutes after oxytocin administration. The metabolite response 
was significantly higher in the 70s versus the 50s and 70s versus the 60s groups (p< 
0.001; p< 0.02, respectively); and there was no significant difference between the 70s 
group and the control group (P>0.36). Luteal function was maintained after oxytocin 
administration in 4/4, 3/4, and 0/3 mares in the 50s, 60s, and 70s groups, respectively. 
Collectively, these results indicate that the luteolytic mechanism returns approximately 
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 In all domestic animals, it is a goal of the owner, producer, trainer, handler, or 
veterinarian to manage behaviors with techniques that provide the greatest opportunity 
for success. In the management of livestock, it is understood that stress associated with 
handling can have an effect on production. The need to address behavioral concerns has 
even given rise to behavior as a veterinary medicine specialty (American College of 
Veterinary Behaviorists). In companion animal species, household pets are often treated 
as family members. In the equine industry, trainability, safety, and performance can be 
greatly impacted by behavior. The expression of behavioral estrus in mares, can have a 
profoundly negative influence on performance [1]. It is common for horse owners to 
approach veterinarians seeking of help to manage these behaviors [2].  
 There are many estrus suppression methods which therapeutically address 
behaviors associated with the estrous cycle. The most popular methods of estrus 
suppression include the use of exogenous progestins, extending the functional span of the 
corpus luteum (CL), suppressing follicular activity, and ovariectomy [3]. The most 
clinically applicable methods used are the administration of exogenous progestins and 
prolonging luteal activity.  
 The synthetic progesterone analog altrenogest, administered orally, is the current 
pinnacle method of estrus suppression. Available as a biologically active oral 
formulation, the use of altrenogest provides the mare with an exogenous form of 
progesterone which simulates the presence of a functional CL and masks the effects of 
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estrogen produced by follicular activity. Altrenogest can be administered at any point in 
the estrous cycle, but requires daily oral treatment with 0.044 milligrams per kilogram 
(mg/kg) and administration for the duration of the desired effect [4]. In addition to the 
cost of this technique, altrenogest also carries safety concerns for those handling the 
product [5,6]. Injectable formulations of compounded long-acting progesterone and 
progesterone analogs have been evaluated as an alternative to oral altrenogest. However, 
the lack of regulation, variability in potency, questionable stability, and potential for 
injection site reactions create variable outcomes. Compounded formulations of 
altrenogest are also not approved by the United States Food and Drug Administration 
(FDA).  
 Various therapeutic techniques to prolong CL function for estrus suppression have 
been described. The use of an intrauterine glass ball has previously been regarded as the 
most common method of prolonging CL function [7]. This method mimics the presence 
of a conceptus and blocks the mechanism of luteolysis, which subsequently maintains the 
luteal tissue in the ovary. Intrauterine glass balls must be inserted and removed by a 
veterinarian. This method of estrus suppression is about 35% effective [8]. Beyond the 
low rates of success, the use of intrauterine glass balls can also have deleterious effects 
on the mare reproductive tract. The accidental placement of more than one glass ball can 
cause glass to fragment inside the mare’s uterus [7]. As an alternative, the use of oxytocin 
as a method of prolonging CL function has gained much popularity as a method of estrus 
suppression [9]. 
 Two protocols have been described for the use of oxytocin as a method of estrus 
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suppression. With knowledge of the date of ovulation (Day 0), 60 international units (IU) 
of aqueous oxytocin can be administered once daily intramuscularly (IM) from 7 to 14 
days post-ovulation [10]. If the date of ovulation is unknown, 60 IU of aqueous oxytocin 
can be administered IM once daily for 29 consecutive days [11].  Multiple studies have 
shown that the use of oxytocin to prolong CL function is ≥ 70% effective. Although there 
is an increase in efficacy in comparison to the use of intrauterine glass balls, the need for 
daily treatment is a drawback to its clinical application.  
To continue refining a more easily applicable oxytocin protocol for prolonging 
CL function, proprietary oxytocin formulation and improved protocols have been studied. 
In a preliminary study, three different proprietary formulations of slow-release oxytocin 
(SR-OT) were tested in an effort to eliminate the need for daily treatment [12]. Of the 
three formulations tested, one appeared to be more efficacious than the others, but 
required the need for further evaluation in comparison to a control group. To further 
evaluate the efficacy of a two-dose protocol, in Experiment 1, we hypothesized that 
administration of 2,400 IU of SR-OT IM once on day 7 and once again on day 10 post-
ovulation would be an effective method of prolonging CL function in comparison to a 
non-treated control group. Consisting of only two treatments, this protocol would 
effectively reduce the number of required injections by 75% (8 treatments vs. 2 
treatments) to achieve the same outcome as previously described oxytocin induced 
methods of estrus suppression. 
Following the evaluation of a proprietary SR-OT formulation in Experiment 1, the 
return of the luteolytic mechanism during the period of prolonged CL function was 
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assessed in Experiment 2. During the normal luteolytic process, prostaglandin F2α 
(PGF2α) is the hormone responsible for luteolysis. While it is understood that oxytocin 
treatment for prolonging CL function disrupts cyclooxygenase-2 (COX-2) expression, it 
is not known when the luteolytic pathway returns after establishment of this prolonged 
state [13,14]. The average length of prolonged CL function is about two months [15]. In 
this study, the return of the luteolytic mechanism was evaluated by measuring an 
oxytocin stimulated pulse of 13,14-dihydro-15-keto PGF2α (PGFM), the main PGF2α 
metabolite. It was hypothesized that there would be a return of the luteolytic pathway in 
mares in a state of prolonged luteal activity. It was also the objective of this secondary 
study to determine when the luteolytic pathway returned in mares that were 
therapeutically treated with oxytocin for the purposes of estrus suppression. This research 
is highly relevant to the equine industry in order to develop additional understanding of 
the return of the luteolytic mechanism. With advanced understanding of this process 
treatments to further extend prolonged CL function for the purposes of estrus suppression 





REVIEW OF LITERATURE 
 
 The equine performance industry greatly values and has a high level of 
expectation for its animal athletes. Mares are no exception to this standard. Veterinarians 
are often approached by clients with the concern of how a mare’s estrous cycle may be 
affecting her level of performance. For this reason, estrus suppression is a common 
practice in mares in all aspects of the industry with an emphasis on top athletes or 
prospects. Although there are many different estrus suppression techniques available, 
they come with mixed efficacy and unique drawbacks to each application. This review 
will investigate the intricate nature and manipulation of mare reproductive physiology, 
and different methods of estrus suppression. The use of oxytocin treatment to prolong CL 
function as an emerging and developing method of estrus suppression, and the return of 
the luteolytic mechanism during the period of prolonged CL function will also be 
discussed.  
 
1.  Estrous Behavior and Performance 
 Behavior conducive to breeding (heat) can be of great benefit in mares that have 
found roles in breeding programs. Estrous behavior in the mare is characterized by 
increased sexual interest in the stallion [16]. Mares can be “teased” in front of a stallion 
to determine the stage of the estrous cycle the mare is in. If the mare displays behavior 
that is indicative of heat, it can be assumed that the mare has a mature follicle 
approaching the point of ovulation and that there is no functional luteal tissue inhibiting 
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the estrogenic behavioral effects. Mares in heat may exhibit behavior including; wide-
based hind limbs, lowered pelvis, raising the tail up and holding to the side, eversion of 
the clitoris (clitoral winking), and frequent voidance of urine. During this follicular phase 
of the estrous cycle the behavior of mares may range from mild interest in the stallion to 
a full display of reproductive signals and acceptance of the stallion mounting and 
copulation [17]. In contrast, mares in the luteal phase of the estrous cycle generally act 
agitated by the presence of a stallion and display aggressive behaviors such as switching 
their tail, pinning their ears back, tensing facial muscles, and biting or kicking at the 
stallion. When elevated, progesterone dominates over the behavioral effects of estrogen 
[18]. 
 Behaviors associated with estrus have been shown to have a profoundly negative 
effect on training and performance [1]. Equine veterinarians often receive requests to 
manage the estrous cycle in performance mares because of difficulty in training and 
performance [19]. Clinical signs that have been associated with performance trouble 
include general difficulty in training, temperament changes, squealing, excessive 
urination, kicking, decline in performance, and abdominal discomfort associated with 
ovulation [2,20]. In performance settings, it is expected that the mare will exhibit a very 
high level of skill and the horse’s disposition is a very important element in its ability to 
perform [21].  
 The first step in considering behavioral management of a performance mare is to 
determine if performance problems are truly related to the estrous cycle. If a mare is 
exhibiting inconsistency in training or performance, an evaluation by a veterinarian may 
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be necessary to rule out an injury or ailment as the cause of the behavior. When the mare 
is deemed to be healthy and sound, the next step is to determine what phase of the estrous 
cycle the mare is in. The mare should be observed in training during both estrus and 
diestrus to determine if estrus suppression is an appropriate treatment option. This sort of 
systematic evaluation can confirm what phase of the estrous cycle the behaviors in 
question are associated with. Using a stallion to tease a mare may be a necessary tool. 
The use of transrectal palpation and ultrasonography, and evaluation of serum 
progesterone concentrations can provide information necessary for a veterinarian to 
determine if follicular activity is associated with the exhibited performance issues. The 
most common issue in performance mares are behavioral changes associated with the 
estrous cycle [2]. When a veterinarian has confirmed association of performance issues 
with estrus, different estrus suppression methods can be implemented as discussed later 
in this review.  
 
2.  Introduction of Key Hormones 
 Reproductive cyclicity involves many different hormones. The interaction of the 
hypothalamus, the pituitary gland, and the ovaries of the mare is referred to as the 
hypothalamic-pituitary-ovarian (HPO) axis. This intricate network of endocrine tissue is 
responsible for most of the key hormones involved in the mare estrous cycle.  
Progesterone is a steroid hormone that is primarily produced during diestrus and 
during pregnancy. Synthesized by the luteal cells of the CL and by the placental unit, 
progesterone is aptly named for its requirement during gestation in mares (and most other 
mammals) [22]. In a diestrus mare, and in early pregnancy, the CL is the main source of 
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progesterone [23]. The placental unit is the main source of progesterone and progestins 
from mid-gestation until term in the pregnant mare [23]. It is classified as a steroid 
hormone as it is derived from cholesterol. The target tissues of progesterone are the 
endometrium and myometrium. This hormone affects the tubular genitalia as well as 
physical and behavioral sex characteristics [23]. Progesterone also interacts with the 
anterior pituitary gland in a feedback system controlling luteinizing hormone. 
Progesterone is commonly regarded as the primary hormone in the maintenance of 
pregnancy [24]. It also inhibits the behavioral effects of estrogen, making this hormone a 
key player in most estrus suppression therapies [3,18]. Estrogen and progesterone have a 
dynamic relationship with antagonistic and synergistic effects. During diestrus, 
progesterone influences the downregulation of estrogen receptors. During estrus, estrogen 
stimulates the synthesis of progesterone receptors [25]. Of these two hormones that 
comprise the main steroid hormones of the mare estrous cycle, progesterone is the most 
dominant [26].  
Estrogen is derived from the granulosa cells of the follicle, as well as the placenta, 
and the embryo. This hormone targets the hypothalamus and anterior pituitary gland and 
has influence on the reproductive tract and mammary gland of the mare [24]. The levels 
of estrogen directly affect sexual behavior of the mare [18]. Estrogen and progesterone 
have counteractive effects on the reproductive tract and on behavior [18]. Uterine tone is 
directly affected by the concentrations of progestins and estrogens [27]. The maximal 
uterine tone is reached during days 16 to 25 of pregnancy when progesterone being 
secreted from the CL is continued and the embryonic vesicle is supplying estrogens [27]. 
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Estrogen and progesterone share many common synthetic factors. Both hormones stem 
from cholesterol derived pregnenolone, but there are two pathways proposed for the 
synthesis of estradiol-17β [23]. One pathway suggests that estradiol-17β is derived from 
progesterone through 17α-hydroxyprogesterone, a second pathway proposes an alternate 
route involving 17α-hydroxypregnenolone and dehydroepiandrosterone.  
Prostaglandins serve many roles in equine physiology. All prostaglandins are 
derived from the cyclooxygenase pathway which converts arachidonic acid (AA) into the 
endoperoxides. These endoperoxides are then converted into various forms of 
prostaglandins. In general, prostaglandins function to control blood flow and activity of 
smooth muscle [23]. PGF2α is regarded as primarily responsible for luteolysis in the 
mare [28]. This hormone is derived from the uterine endometrium and promotes uterine 
tone and contraction by targeting the CL as well as the myometrium [24]. PGF2α targets 
the CL to cause luteolysis in late diestrus by acting through systemic circulation [23]. 
Unlike ruminants, the vasculature of the mare reproductive tract does not provide a local 
pathway for delivery of PGF2α to the ovary [29]. Instead, systemic circulation is required 
for PGF2α to target the CL and cause luteolysis. Systemic circulation targeting the CL 
can be utilized pharmacologically to manipulate the length of diestrus. Both native and 
synthetic forms of PGF2α are commercially available and can be used to terminate a CL 
at a desired time point [23]. 
 Oxytocin is a neuropeptide synthesized in the hypothalamus and stored in the 
posterior lobe of the pituitary gland. Unlike most other mammals, oxytocin is not 
synthesized by the CL in mares [23]. Oxytocin primarily targets the endometrium and 
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myometrium in non-lactating mares. At the level of the endometrium, endogenous 
oxytocin stimulates synthesis and secretion of PGF2α. At the myometrium, oxytocin 
stimulates uterine contractions and motility [23]. In lactating mares, oxytocin also targets 
the myoepithelial cells of the mammary gland to stimulate the release of milk [24]. 
Therapeutically, oxytocin has many functions, some of which are contradicting. 
Exogenous oxytocin treatment can be used to enhance uterine clearance post-breeding, 
treat post-partum mares with a retained placenta, stimulate milk let-down, rarely aid in 
the timing of parturition, and also serve in luteolytic and anti-luteolytic functions [30,31]. 
This review will discuss in detail the ability of oxytocin to both stimulate PGF2α 
secretion from the endometrium, as well as its ability to inhibit the synthesis of PGF2α.  
Gonadotropin releasing hormone (GnRH) is a neuropeptide hormone that is 
synthesized at the surge center of the hypothalamus. Every vertebrate species has the 
GnRH gene in its genome [23]. By way of the hypothalamic-pituitary portal system 
GnRH targets the gonadotroph cells of the anterior pituitary gland and initiates a cascade 
of hormonal events [23]. During the breeding season, elevated levels of GnRH stimulate 
the release of the pituitary gonadotropins, follicle stimulating hormone (FSH) and 
luteinizing hormone (LH), in higher levels than during the non-breeding season [23,24]. 
The pituitary gonadotropins serve the same purpose among all domestic animals [23]. LH 
and FSH are biochemically classified as glycoproteins and are considered to be the 
gonadotropins involved in the mare estrous cycle. Both of these hormones are 
synthesized at the anterior lobe of the pituitary gland by the gonadotroph cells. FSH 
targets the granulosa cells of the ovary to stimulate follicular development and estradiol 
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synthesis. LH targets the theca interna and luteal cells of the ovary [24]. LH plays an 
important role in the process of ovulation and the formation of the CL which in turn 
produces progesterone. The chorion of the placenta also produces equine chorionic 
gonadotropin (eCG) in the pregnant mare. This hormone is synthesized by endometrial 
cups and acts in a luteotrophic fashion [23]. 
The mare estrous cycle has many physiologic components. The hormones of the 
HPO axis influence every aspect of reproductive behavior, conception, and seasonality.  
 
3.   The Mare Estrous Cycle 
3.1  Seasonality of the Mare Estrous Cycle 
The mare is seasonally polyestrous with regular follicular activity corresponding 
to duration of day length. The normal physiologic breeding season for mares is prompted 
by longer days and shorter nights, which in the northern hemisphere is typically late 
spring until fall (April through October) [32]. The increase in day length directly 
correlates to the number of mares having normal cyclic estrous activity [23]. This timing 
naturally allows for mating at the time of year that subsequently provides a newborn foal 
with optimal environmental conditions and nutrition for survival [23].  
The physiologic breeding season is flanked on both sides by transitional periods 
of inconsistent follicular activity [33]. These phases are composed of irregular estrus 
behavior as the mare transitions from a winter anovulatory state into the photoperiod-
induced breeding season and back into winter anestrous. Often, the transition into the 
winter anovulatory period is marked by a state of prolonged CL activity [34-36]. This 
phenomenon of long day breeding is regulated by a chain of hormonal and environmental 
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interaction that influence the ovaries (Fig. 1). 
 
 
Fig 1. Mechanism for seasonality of the mare estrous cycle (Ginther, 1992) 
 
The amount of light provided from daylength or artificial light sources directly 
stimulates photoreceptors in the eye. The photoreceptors then initiate a neuropathway 
effecting pineal secretion of melatonin. During shorter days of the year there is more 
melatonin secreted by the pineal gland than in longer days of the year. Melatonin 
secretion has an inverse relationship with GnRH secretion. Increased daylength decreases 
melatonin secretion and allows for increased GnRH leading to production and release of 
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LH and FSH during the breeding season. Systemic circulation delivers gonadotropins to 
the ovaries of the mare (Fig. 2). Of course, some mares exhibit behaviors and follicular 
activity that are inconsistent with the influence of daylength. Up to 35% of mares may 
exhibit unseasonable estrous associated with inconsistent follicular activity and some 
mares (10-15%) may continue their estrous cycle through the winter [37]. 
 
 
Fig. 2. Feedback mechanisms and seasonal regulation of reproductive organs 
involved in the HPO axis (Samper, 2009).  
 
 
3.2 Advancing the Onset of the Ovulatory  
 Season via Artificial Lighting 
 Understanding the effects of daylight on reproductive seasonality has provided 
advantageous tools to broodmare managers. With growing pressure to produce foals with 
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birthdays closer to the first of January, the artificial manipulation of daylight allows for 
advancement of regular follicular activity in the mare [38]. A total of 16 hours of light is 
sufficient to hasten the onset of the ovulatory season [39]. Artificial lighting should be 
initiated approximately 60 days before the desired beginning of ovulatory activity. The 
most preferred method of artificial lighting is to provide supplemental light at the end of 
each day to reach a total of 16 hours of light [38]. In this method, if sunrise was 8:00 AM 
and sunset was 6:00 PM, a source of artificial light would be illuminated from just before 
sunset until 12:00 AM (midnight) to reach the total prescribed exposure of light. 
 
3.3  The Mare Estrous Cycle 
There are two phases of the mare estrous cycle, estrus and diestrus, which are 
characterized by anatomical structures correlated with behavioral receptivity to the 
stallion. Estrus, diestrus, and the cycle in total, are determined to have an average length 
of 6.5, 14.9, and 21.7 days, respectively [23]. The estrus phase is reported to have the 
most deviation in length and may range from 3 to 12 days, but most often falls within five 
to seven days [19]. During the estrus phase, multiple follicles are present on the ovary 
with one or two dominant follicles as the main structures present on the ovary. These 
follicles produce estrogen, which promotes behaviors facilitating copulation with the 
stallion in the absence of high circulating concentrations of progesterone. The estrus 
phase is physiologically characterized by the growth and ovulation of a mature follicle 
during the absence of progesterone. The follicle, being a structure of transient nature, 
ovulates and transitions to become the CL. During the diestrus phase, which lasts about 
two weeks, the CL is the dominant structure present on the ovary. The CL produces 
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progesterone which promotes an endometrial environment suitable to maintain 
pregnancy. Progesterone also inhibits the behavioral effects of estrogen [18]. As a result, 
the mare is unwelcoming of the stallion, and sometimes even hostile towards him. The 
estrous cycle resets as the CL undergoes luteolysis in late diestrus of the non-pregnant 
mare (approximately day 14) and a new dominant follicle matures. 
 
3.4  Anatomy of the Mare Reproductive Tract 
The mare reproductive tract is a unique system that differs in many ways from 
other common farm species. The reproductive tract consists of the two ovaries, the 
tubular genitalia (oviducts, uterus, cervix, vagina, vestibule, and vulva), as well as the 
mammary glands (Fig. 3).  
The ovaries are the master control center of the mare reproductive tract [23]. The 
ovaries of the mare are slightly larger than those of other common farm animals with a 
length of 4-8 centimeters (cm), width of 3-6 cm, and height of 3-5 cm. Individual mature 
follicles, the CL, and the ovary as a whole compared by body weight are larger than other 
farm animal species as well [23]. The ovary is kidney bean shaped with a concave surface 
known as the ovulation fossa on the ventral edge (Fig. 4). The ovary of a young filly is 
oval shaped, but a discernable ovulation fossa is formed by five months of age and the 
kidney bean shape is apparent by seven months of age [40,41]. The ovary positioning 
within the body cavity can be inconsistent as they may be moved by the intestines. The 
right ovary is on average 15cm caudal to the right kidney, as the left ovary is in closer 
proximity to the left kidney because that kidney has a more caudal positioning itself [42]. 




Fig. 3. The equine reproductive tract (A: Dorsal view, B: Lateral view) (Ginther, 1992). 
 
estrogens. A mature follicle will ovulate to release the oocyte for fertilization and then 
[23]. In opposite fashion of most other farm species, the medullary region of the mare 
ovary is superficial. This medullary region of the ovary is the vascular zone of the ovary. 
The cortical region of the ovary lies deeper in the organ and only appears at the surface of 
the ovulation fossa. Unique to equine species, the ovulation fossa is the only point at 
which ovulation ensues [23]. As ovulation delivers an oocyte into the tubular 




Fig. 4. Representative drawing of the morphological characteristics of a mare ovary 
(Samper, 2009). 
 
function of the follicle is to house and develop the oocyte while actively producing  
transition into a CL. The CL serves only in an endocrine fashion as it produces 
progesterone. The follicle and CL operate as transitional endocrine glands controlling the 
environment of the tubular genitalia and behavior of the mare. 
 
4.  Follicular Dynamics 
 The underlying purpose of the mare estrous cycle is to develop and mature a 
follicle with the intent of ovulation and delivery of the maternal oocyte to the oviduct. 
These follicular dynamics begin at a histological level in the form of primordial follicles, 
long before visualization by transrectal ultrasound is possible. The primordial follicle is 
defined as the point at which an oocyte is arrested at a meiotic state and is enveloped in a 
layer of squamous cells [23]. This stage of follicular development is reached not long 
after a filly is born. As the primordial cell transitions into a new structure called the 
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primary follicle, the squamous cells are converted into cuboidal cells which eventually 
become the granulosa layer [23]. The transition from primordial to primary follicle is 
regulated in the mare by unknown mechanisms. In other mammals, it takes months for a 
primordial follicle to develop into a fully mature follicle with development of an antrum. 
An accurate timeline of folliculogenesis including this primordial-to-primary stage has 
not been determined in the mare. The number of primordial follicles that transition 
together is lower in mares than in cows. Mares may have about 100 follicles developing 
while cows develop 300 [23]. The mare, as with most other species, has not been reported 
to have mitotic development of oogonia. This presumably determines that there is a 
limited number of primordial follicles stored in the ovaries of each mare which cannot be 
replenished.  
 As primary follicles continue to develop, a great portion of small follicles grow 
and then undergo atresia. Atresia is the regression of these non-dominant follicles. 
Although the dynamics of small follicles are not well documented in mares, it is assumed 
that these follicles continually grow and become atretic through every cycle and 
reproductive state (estrus, diestrus, anestrous, pregnancy, pseudopregnancy, and 
postpartum) [43]. The group of follicles that grow simultaneously are referred to as a 
“major follicular wave.” This follicular wave consists of five to ten follicles which grow 
at a rate of 2 to 4 mm per day [38]. The follicles within a wave typically begin growing 
synchronously, but eventually disassociate from one another during the selection process 
as one or two follicles continue to develop towards maturity and the others of the group 
undergo atresia. This differentiation in follicle outcome occurs when the largest follicle 
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reaches 20 to 25 millimeters (mm) [38].  
 The follicle that is most favored (grows the fastest) is referred to as the dominant 
follicle. This physiologically selected follicle grows to a large diameter (>30 mm). The 
mare, being a monovulatory species, will (in most cases) only develop one follicle that 
reaches maturity [23,44]. The dominant follicle will either ovulate, or it will regress 
(anovulatory wave). Secondary waves are also possible in the mare, in which, a second 
wave of growing follicles may ovulate a second dominant follicle during a state of 
diestrus [23]. Diestrus ovulations are more common in Thoroughbreds than in Quarter 
Horses or ponies [45].  
 Most often, the major follicular wave occurs in the form of a primary wave during 
late diestrus. This wave of follicles gives rise to the ovulation occurring during the 
follicular phase (estrus) of the estrous cycle [23]. The dominant follicle of the primary 
wave is carrying an oocyte that can potentially be fertilized. The primary wave is 
detectable by transrectal ultrasonography and palpation at about mid diestrus [43,46]. 
During the selection process, the dominant follicle will disassociate from the cohort of 
smaller follicles about seven days before subsequent ovulation. The disassociation is 
recognizable by the difference in growth rate (diameter) of the follicles.  
 The mare estrous cycle only consists of one or two follicular waves. The 
interovulatory interval (IOI) is determined as the number of days from one ovulation until 
the next. In estrous cycles with two follicular waves, there is one primary follicular wave 
producing a potentially fertilizable oocyte, and an earlier secondary wave, which may 
produce a large anovulatory follicle, or a diestrus or secondary ovulation [47]. Breed also 
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has influence on the follicular activity of the mare. Quarter Horses and pony breeds have 
lower levels of follicular activity than that of Thoroughbred and Standardbred mares 
[46,48]. 
 
5.  Hormonal Aspects of Follicular Dynamics 
 Follicular waves start with about 100 primordial follicles, but end with a single 
dominant follicle reaching ovulation [23]. The dominant follicle will subsequently 
become the CL after ovulation. Slightly before the time of ovulation, a gradual increase 
in hypothalamic GnRH results in elevated FSH for the duration of diestrus. This 
influences the developing follicles to synchronously grow into small antral follicles. As 
the follicles in the primary wave increase in size, they also increase in the production of 
inhibin from the follicular granulosa cells. Inhibin works as a negative feedback for FSH. 
This negative feedback decreases the amount of FSH gradually from about 13 days after 
ovulation (Fig. 5).  
The decrease of FSH and increase of LH and inhibin continues throughout the 
point of luteolysis. At about day 14, PGF2α from the endometrium systemically 
circulates in the mare targeting the CL. PGF2α originates from the non-gravid uterus of 
the mare and is stimulated by oxytocin in a pulsatile manner [49,50]. During this time the 
follicles are still growing at a generally synchronous rate, but the number of recruited 
follicles has dropped to about 10 or less because of unknown mechanisms. By day 17, the 
CL has regressed significantly in size and function. Without the influence of 




Fig. 5. Profiles of hormones associated with the equine estrous cycle (Samper, 2009). 
 
Follicular estrogen increases and the mare becomes more receptive to mating with 
the stallion. After the dominant follicle is selected it continues to mature and develop, 
producing inhibin and estrogen, as the subordinate follicles undergo atresia. The 
dominant follicle will typically grow to 35 mm or larger before ovulation. Follicular 
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estrogen typically peaks just before ovulation and has a synergistic effect with LH 
resulting in low levels of FSH [38]. The dominant follicle often becomes irregular or 
guitar pick shaped just before ovulation. This is because of the follicle’s conformation to 
the ovulation fossa of the ovary. Ovulation is stimulated by a surge of LH [51]. The 
rupture and release of the oocyte by the dominant follicle characterizes ovulation and 
marks the end of one IOI and the beginning of the next.  
After ovulation, the once dominant follicle begins to transform by undergoing 
luteinization to create the CL. Unlike the CL in ruminants which has a delay in the 
production of progesterone after ovulation, in the mare, the CL begins producing 
progesterone immediately after ovulation [23,52]. Within 24 to 48 hours, progesterone 
counteracts the behavioral effects of estrogen making the mare antagonistic towards 
mating with the stallion [18]. LH and inhibin steeply decrease after ovulation as FSH 
increases and remains high during the luteal phase of the estrous cycle. Small pulses of 
LH continue for a short period of time after ovulation to aid in the development of the 
CL.  
 
6.  Luteolysis 
The luteal phase of the estrous cycle in mares is characterized by the presence of a 
CL and the secretion of progesterone. This hormone influences behavior as well as the 
tubular genitalia of the mare. Specifically, progesterone prepares the reproductive tract to 
receive an embryonic vesicle and begin early gestation. If an embryonic vesicle is 
recognized within the uterus, complex mechanisms block the occurrence of luteolysis. 
With the absence of an embryonic vesicle, the uterus maintains the ability to reset and 
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initiate a new estrous cycle. 
As PGF2α is secreted in pulses over a 23-hour period, the CL goes from being the 
controller of reproductive cyclicity in the mare, to a remnant of the past [53]. Luteolysis 
results in the loss of function of the CL as a consequence of targeting by PGF2α [54]. At 
about 14 days after ovulation, a non-gravid uterus signals that it is ready to enter another 
follicular phase. In order to lyse the CL, the uterus secretes PGF2α. This luteolytic 
hormone is secreted in small pulses before luteolysis, but during the time of luteolysis the 
concentration of PGF2α is about six-times higher than before [55]. This transition from a 
pre-luteolytic to a luteolytic stage only takes about one hour [55]. As marked by 
progesterone concentrations, the events of luteolysis begin on day 14 and are concluded 
around day 17 when progesterone falls below 1.0 nanogram per milliliter (ng/mL) [38]. 
A complete understanding of luteolysis in the mare has yet to be established and is a 
reason that our lab has endeavored to further characterize this process.   
 
6.1  The Role of the Uterus in Luteolysis 
 The relationship between the uterus and the CL is very important in the mare 
estrous cycle. Uterine mechanisms are responsible for the maintenance or destruction of 
the CL [56]. In the non-pregnant mare, the uterus is responsible for the secretion of 
PGF2α. In the pregnant mare, the uterus undergoes specific changes which disrupt the 
processes of luteolysis [57].  
 In the non-pregnant mare, luteolysis occurs as a result of PGF2α secretion and 
systemic delivery to the CL [58]. The regression of the CL as a result of pulsatile PGF2α 
secretion marks the end of diestrus [59]. The vasculature of the mare reproductive system 
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dictates that uterine derived PGF2α must travel systemically to reach the CL [29].  This 
delivery is different than most other farm animal species which exploit localized 
pathways of vasculature [60]. The differences in luteolytic pathways between ruminants 
and horses have been studied extensively by Ginther et al. to uncover how the vasculature 
(local vs. systemic) affects the route of PGF2α [61]. The close proximity of the utero-
ovarian vein and the ovarian artery in ruminants allows for a local transfer of PGF2α 
from the uterus to the ovary. It is assumed that the intimate relationship of anti-
directional blood vessels allows for the ability of the animal to exploit an amount of 
counter-current exchange. This transfer is possible because PGF2α is fat soluble and can 
travel along lymphatic and venous vessels to make its way to the ovary [62]. Because of 
the local nature of luteolysis in ruminants, there is also an ipsilateral association between 
the uterus and the CL in the recognition of pregnancy [63].  
 In the mare, the vasculature of the uterus and ovary do not share the same intimate 
relationship that is seen in cattle and secretion of PGF2α targeting the CL occurs 
systemically [29]. The systemic circulation targeting the ovary has been demonstrated in 
many studies. Using three different routes of administration (local: intrauterine or 
intraluteal; systemic: IM) and three different doses of PGF2α (0, 0.25, or 1.25 mg) there 
was no significant difference in the route of administration on the occurrence of 
luteolysis in mares [64]. The actions of systemic circulation and delivery of uterine 
secretions are further supported by embryonic characteristics of the maternal recognition 
of pregnancy in the mare [63]. Embryonic mobility in the mare has no ipsilateral or 
unilateral relationship between the uterus and ovary (discussed in detail later in this 
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review) [65].  
The half-life of PGF2α is very short, making this hormone very hard to measure 
directly in the systemic circulation. The main metabolite of PGF2α in horses and cattle is 
13,14-dihydro-15-keto PGF2α (PGFM) [66,67]. Because the half-life of PGFM is longer 
than that of PGF2α, the concentration of circulating metabolite is often measured in order 
to represent concentrations of PGF2α. In comparisons of progesterone concentrations in 
response to simulated PGFM pulses, it is apparent that complete luteolysis requires 
multiple pulses of PGF2α [68]. During the preluteolytic window, rhythmic PGFM pulses 
were not detected, but rhythmic pulses of PGFM were indicated in seven of nine mares 
during luteolysis and post-luteolysis in a study by Ginther et al. [55]. The requirement of 
sequential pulses of PGF2α is also characteristic of luteolysis in cattle [69]. Following 
luteolysis, the remaining remnant of the CL is referred to as the corpus albicans (CA) 
[70].  
 
6.2  The Role of Oxytocin in Luteolysis 
The uterine preparation for luteolysis begins long before the luteolytic window. 
Although our knowledge of the luteolytic mechanism is improving, there is room to 
further characterize the event of luteolysis. Oxytocin has been described in both horses 
and ruminants as an important factor in the chain of the luteolytic process [50,61]. In 
ruminants, it is known that oxytocin from the posterior pituitary gland targets its 
receptors at the uterine endometrium [61]. The interaction of estrogens with the 
endometrium during late diestrus act as a proliferative stimulant of oxytocin receptors in 
ruminants [71,72]. It has been shown that the presence of steroid hormones is critical for 
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the development of oxytocin receptors [71]. A positive feedback luteolytic mechanism 
involving oxytocin and PGF2α has been described for ruminants. Posterior pituitary 
derived oxytocin targets the endometrium stimulating the synthesis and secretion of 
PGF2α which targets the CL. In ruminants, the CL provides an additional source of 
oxytocin which continues to target the endometrium creating a secondary luteolytic pulse 
of PGF2α [73]. In horses, the interaction between oxytocin and uterine PGF2α are not 
understood as well.  
In mares, the CL is not described as a source of oxytocin involved in luteolysis 
[74]. Oxytocin in mares is involved in luteolysis by way of a different positive feedback 
mechanism. The endometrium and the posterior pituitary gland have both been shown to 
be producers of oxytocin [49,50]. It is proposed that small amounts of uterine derived 
oxytocin interact with oxytocin receptors present on the endometrium in late diestrus and 
consequentially stimulate PGF2α secretion which targets the CL. The circulating PGF2α 
influences the secretion of oxytocin from the posterior pituitary which then targets the 
endometrium causing a dramatic luteolytic increase of PGF2α [75]. As mentioned 
previously, multiple pulses of PGF2α are necessary for complete physiological luteolysis 
[68].  
The pathway of oxytocin develops some complexities at the endometrium where 
it stimulates PGF2α synthesis and secretion. As oxytocin targets its receptors at the 
endometrium, it stimulates the activation of phospholipase A2 (PLA2), which is critical 
in the release of arachidonic acid (AA) from the cell membranes [76,77]. AA is the 
substrate necessary for all prostaglandin synthesis through the cyclooxygenase pathway. 
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The cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) proteins convert AA 
into prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2), which are known as 
endoperoxides. PGH2 is converted to PGF2α by mediation of prostaglandin F synthase 
(PGFS) [13]. The involvement of COX-2 in luteolysis and maternal recognition of 
pregnancy is greater than the involvement of COX-1. The oxytocin-prostaglandin 
pathway has been evaluated in various studies. It has been shown that oxytocin 
administered during late diestrus results in an immediate spike of PGFM [78]. It has also 
been determined that PGFM in response to oxytocin reaches a maximum around the 
window of luteolysis [79].  
At the time of luteolysis in the mare, COX-2 is highly expressed in the 
endometrium. This parallels the expression of COX-2 in ewes and in cows during late 
diestrus [80,81]. Alternatively, COX-2 expression is significantly lower in the pregnant 
mare. It is assumed that the equine conceptus inhibits COX-2 and subsequently interferes 
with the synthesis of PGF2α and the luteolytic process [76].  
The presence of oxytocin receptors at the endometrium also fluctuates depending 
on the phase of the estrous cycle of the mare [78]. Prior to day 10 after ovulation, the 
concentrations of oxytocin receptors and the expression of COX-2 are too low to create a 
sufficient luteolytic response [76]. After day 10 post-ovulation, the required enzymes and 
oxytocin receptors are expressed in high enough quantities to cause luteolysis. There is a 
direct correlation between the ability of the endometrium to secrete PGF2α and elevated 
concentrations of oxytocin receptors in late diestrus in normal cycling mares [82].  
 Although oxytocin is proposed as a key element in the processes of luteolysis, it 
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has also been realized as a clinically applicable method to inhibit the functions of 
luteolysis. These contradicting effects are achievable through a greater understanding of 
the hormonal aspects controlling luteolysis.  
 
7.  Maternal Recognition of Pregnancy in the Mare 
 The mare exhibits some unique features in the events leading to maternal 
recognition of pregnancy. The concept of embryonic mobility and the lack of 
understanding of the chemical signaling from the embryo may be the most puzzling, but 
crucial, of them all. After fertilization of the oocyte in the oviduct, the embryo undergoes 
oviductal transport.  Beginning three to four days after fertilization, embryonic secretion 
of prostaglandin E2 (PGE2) stimulates transport of the embryo toward the utero-tubal 
junction [83]. PGE2 secretions from the embryo are significantly higher around day five 
to six and elevate to even greater concentrations following uterine entry around day six 
[83]. Continuous oviductal administration of PGE2 has been shown to accelerate the 
embryonic stage of oviductal transport [84]. Although the embryo secretes appreciable 
amounts of PGE2 and a pharmacologic dose of PGE2 stimulates prolonged CL function 
in non-pregnant mares, there is no conclusive evidence that PGE2 is responsible for 
maternal recognition of pregnancy in the mare [85,86].  
 After the embryo enters the uterus, it is able to be observed by transrectal 
ultrasound around nine or ten days after ovulation [87]. The mobility of the equine 
conceptus in the uterus is vital to the maternal recognition of pregnancy, and is a very 
distinguishable feature compared to other domestic species [88]. Embryonic mobility 
fluctuates from entry into the uterus until fixation, and can be visualized by the use of 
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transrectal ultrasonography. The amount of mobility peaks between days 11 and 14 
during which time the embryo may be traversing across the endometrium more than 12 
times a day [89]. This extensive travel of the embryo is a physical requirement for the 
maternal recognition of pregnancy. When embryo mobility was artificially restricted to 
one uterine horn; one uterine horn and the uterine body; or one horn plus the uterine body 
and 80% of the second horn; one of five, two of four, and four of four mares successfully 
maintained pregnancy, respectively [90]. The previous example indicates the necessity of 
the embryo to freely travel and interact with at least two-thirds of the endometrium. This 
study further demonstrated the necessity of progesterone to maintain pregnancy [90]. 
When the embryo in mares was restricted to one uterine horn and the mare was 
subsequently supplemented with progestins, pregnancy was maintained. 
 The requirement of embryonic mobility is clear, but the exact mechanisms by 
which the embryo inhibits luteolysis are not clear. COX-2, a key enzyme in the pathway 
of prostaglandin synthesis, is inhibited by the presence of the conceptus in the uterus 
[76]. It is hypothesized that the disruption of a preliminary step to COX-2 expression 
may be an underlying cause to its inhibition. There is also a disruption of oxytocin 
receptor expression in early pregnancy. Oxytocin receptor expression is similar in 
pregnant and non-pregnant mares on day 12, but is significantly lower in pregnant mares 
than in non-pregnant mares on day 14 post-ovulation [91].  
 In comparison to other common farm animal species, there is a lack of knowledge 
of conceptus derived chemical signaling for the purposes of maternal recognition of 
pregnancy. In pregnant ewes and cows, ovine and bovine-interferon tau play an essential 
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role in the prevention of luteolysis [92,93]. In swine, conceptuses secrete multiple 
interferons, but the role of those interferons are not known to directly affect pregnancy 
[93]. Conceptus derived estrogens inhibit luteolysis in swine by influencing upregulation 
of prolactin receptors and blocking prostaglandins from being delivered to the ovaries via 
uterine vasculature. Instead, prostaglandin is deviated towards the uterine lumen where it 
is metabolized to a form that will not cause luteolysis [94]. In mares, neither estrogen nor 
an interferon component have been identified as a significant chemical signal for the 
maternal recognition of pregnancy. In a 1994 study by Vanderwall et al., eleven non-
pregnant mares were treated with continuous intrauterine infusion of 6 μg/day of 
estradiol-17β [85]. Although six of the eleven mares exhibited prolonged luteal function 
until day 30 post-ovulation, it was determined that treatment with estradiol-17β was not 
significantly different from sham-treated mares in which four of eleven mares exhibited 
prolonged luteal function (P = 0.34). There has not been any evidence of an interferon-
type gene associated with the equine embryo [95].  
 The underlying mechanisms for the inhibition of the luteolytic pathway in 
pregnant mares are not completely understood. More research must be done on this 
intricate event as complexities of equine pregnancy are unique and comprise an extensive 
list. 
 
8.  General Goal of Estrus Suppression 
 Some mares exhibit unwanted behaviors that are not associated with injury or 
ailment but adversely impact performance. Mare owners may choose to evaluate behavior 
in correspondence with the mare’s estrous cycle to determine if the undesirable behavior 
31 
 
is correlated with the estrus phase. During estrus, a mare may become difficult to train or 
ride, may exhibit sensitivity in her flanks, and show common signs of estrus behavior. If 
the mare’s problematic behavior is carefully evaluated and determined to be directly 
associated with estrus, mare owners may choose to address this problem using estrus 
suppression techniques.  
 The goal of all estrus suppression techniques is to address the deleterious 
behaviors associated with the estrus phase of the cycle. By accomplishing this goal, 
performance mares can compete at their full potential without the distractions of the 
estrous cycle taking effect, mare owners can address estrous related behavior to work in a 
safer environment with their horses, and the behavior of a mare can become more 
consistent to aid in the detection of injury or illness.  
The most common estrus suppression therapies can be grouped into two general 
methods. First is the administration of exogenous progesterone, which is most commonly 
performed with the use of oral altrenogest supplementation. The second method is the 
therapeutic maintenance of CL function. By preserving CL function, the mare will have a 
continued source of endogenous progesterone. The presence of progesterone serves to 
counteract the behavioral effects of estrogen which are high during estrus. In a typical 21 
to 22-day estrous cycle, a mare may exhibit estrus behaviors for five to seven days, 
sometimes even longer [18].  
Several techniques to suppress estrus behavior have been examined with varied 
success. The administration of oral exogenous progestins is currently the most prevalent 
method to suppress estrus, but this method also has associated risks and consequences. 
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The oil based altrenogest products are easily absorbed through the skin creating risk to 
human administrators. The FDA reported in 2018 that their agency had received over 130 
reports of accidental human exposure to altrenogest products. Most of the reports 
regarding altrenogest indicated adverse effects in the menstrual cycles of women, and 
decreased libido in men [6]. Besides the risk to human health, most altrenogest products 
are expensive and require daily oral administration. In previous years, the use of an 
intrauterine marble was perceived to be the best method of prolonging CL function for 
estrus suppression, but this method has since been documented to have deleterious 
reproductive consequences [7]. As an alternative to intrauterine glass marbles and daily 
oral progestins, several therapies using oxytocin have been explored. Oxytocin therapies 
for estrus suppression inhibit the luteolytic mechanism causing luteal activity to be 
sustained. 
There are additional methods of estrus suppression that involve immunological 
manipulation, surgery, or the establishment of pregnancy. Therefore, the following 
review will summarize the current body of research available on literature on all methods 
of estrus suppression in mares. Methods involving oxytocin are considered a hormonal 
method of sustaining endogenous progesterone and are described in a stand-alone section. 
 
9.  Prolonged Luteal Activity 
 The occurrence of prolonged CL function in mammals is quite a common 
phenomenon. Some of the terms that can be used to describe the continual function of a 
luteal gland are “prolonged luteal activity,” “persistent CL,” or “prolonged CL function.”  
The term “prolonged diestrus” does not imply a CL deriving from an ovulated follicle, 
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but rather suggests an extended period of diestrus behavior as the mare is not receptive to 
a stallion. In mares, the occurrence of this prolonged secretion of progesterone is often 
associated with pregnancy, but can also occur spontaneously in non-pregnant mares. The 
prevalence of idiopathic prolonged luteal activity in mares is about 10% and lasts for 
about two months [15]. Ginther describes prolonged luteal activity as the determination 
that life of a given luteal gland has been extended [96]. It is generally accepted that estrus 
suppression techniques which prolong luteal activity are successful if progesterone 
concentrations remain above 1.0 ng/mL for a minimum of 30 days. The presence of 
progesterone greater than 1.0 ng/mL indicates a functional CL present on the ovary of the 
mare, but there is a chance that progesterone may be produced by a secondary CL or a 
diestrus ovulation producing a subsequent CL. The occurrence of diestrus ovulations in 
the mare or secondary follicles undergoing luteotrophic transitions influences research. 
Most studies investigating prolonged CL function use transrectal ultrasonography and 
palpation in addition to serum progesterone evaluation. 
 
10.  Hormonal Methods of Estrus Suppression 
10.1  Oral Progestins (Altrenogest) 
The current gold standard for estrus suppression therapies available to 
practitioners is the oral progestin altrenogest which was approved for use in mares by the 
FDA in 1983. Although altrenogest is now available in FDA approved generic 
formulations, the most common label name is ReguMate® from Merck Animal Health 
(Intervet, Inc.). Oral altrenogest is recommended for use at a dosage of 0.044 mg/kg 
daily. Although there is a great benefit in altrenogest’s ease of use, there are also 
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disadvantages to its use. Altrenogest is very absorbable through the skin and can be 
unsafe for administration by women of childbearing age, or pregnant women. This oral 
administration of altrenogest can also become very expensive and calls for daily 
treatment of the mare.  
 
10.2  Injectable Progestins 
Since the 1960s, progesterone in oil has been used to suppress the behavioral 
effects of estrous in mares [97]. The use of exogenous progesterone was accepted as a 
method of behavioral estrus suppression at a dose of 0.2 mg/kg. Although progesterone in 
oil was deemed to be effective, the requirement for daily administration and prevalence 
of injection site reactions were undesirable [19]. In an effort to improve the clinical 
application of injectable progesterone, a compounded version was created in a long-
acting formulation of 1.5 grams (g). This formulation successfully maintained serum 
progesterone concentrations above 1.0 ng/mL for about 10 days, but did not eliminate the 
injection site reaction [98]. There are also compounded injectable altrenogest 
formulations, which are not FDA approved, but have been reported to block estrous 
behavior for 12 and 15 days in doses of 225 mg and 450 mg, respectively.  In the study of 
an injectable 500 mg dose of altrenogest it was reported that estrous behavior was 
suppressed for approximately 30 days [99]. Although compounded long-acting 
progesterone and altrenogest are not approved by the FDA, compounded long-acting 
altrenogest is available in Australia by the name of Readyserve from Ceva Animal 
Health.  
Medroxyprogesterone acetate (MPA) is an injectable long-acting progestin that 
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has been used in women as a human contraceptive (Depo-Provera, Pfizer). MPA has 
shown to be efficacious as a tool for wildlife contraception and is even used in some zoos 
for the uses of estrus suppression, contraception, or even management of pregnancy (St. 
Louis Zoo, St. Louis, MO). This therapy is also effective in queens and bitches, but 
comes with an array of undesirable side effects [100]. In mares however, this biological 
progestin does not have the same effect on the natural reproductive cycle. Although there 
are anecdotal reports of the use of MPA to address performance problems in mares, 
research shows that mares treated with MPA continue to display estrous behavior in a 
normal pattern [101]. Mares injected intramuscularly with 1,600 mg of compounded 
MPA on day 7 post-ovulation and repeated doses of 400 mg on days 14, 21, 28, 35, and 
42 post-ovulation exhibited no deviation of estrous behavior in comparison to a saline-
treated control group [101]. The treated group also showed no differences in follicular 
activity, progesterone or LH concentrations.   
 
10.3  Off-Label Implants 
Different types of implanted devices have been used in cattle for estrous cycle 
synchronization and for improvements in feedlot performance. These devices most often 
use progestins to influence the effects of behavioral estrus. Synovex-C ® (Fort Dodge 
Animal Health, Overland Park, KS) and Controlled Intravaginal Drug Release (CIDR) 
devices have been hypothesized to be efficacious for the purpose of estrus suppression in 
mares, but research shows that neither treatment is successful [2,19]. It is hypothesized 
that these implants do not work for the purposes of estrous suppression in mares because 
of the inability of great enough quantities of the hormone to be absorbed [102]. 
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Other hormonal implants have been tested with varied success. Deslorelin acetate 
is one treatment that has mixed use and variation of efficacy. Most often, GnRH analogs, 
such as deslorelin, are used for their intended purposes to aid or hasten the ovulation of a 
follicle greater than 35 mm in diameter [103-105]. Deslorelin, in an implantable pellet 
form, is known as Ovuplant. In one study, most mares that were administered two 2.1 mg 
Ovuplant doses at one treatment exhibited suppressed follicular activity for more than 30 
days [106]. It was hypothesized that the administration of three 2.1 mg Ovuplant doses at 
one treatment would influence the ovaries of the mare to become quiescent. Although the 
increased dose of the GnRH analogue did increase the IOI to 36.8 days, it did not 
manifest into arrest of ovarian function [107].  
Nogestomet (Crestar, Intervet Australia, Bendigo East Victoria, Australia) and 
Levonorgestrel (Norplant, Wyeth, Collegeville, PA) have both been marketed as methods 
of estrus suppression in mares, but there is a shortage of refereed information available to 
determine the reliable efficacy and treatment protocol.  
 
10.4  Glucocorticoids 
 Reports have shown successful suppression of estrus using glucocorticoids. In a 
1982 study, by Asa and Ginther, 30 mg/day of dexamathosone was administered starting 
on day 10 post-ovulation. Treatment with this synthetic glucocorticoid successfully 
suppressed estrous behaviors and interfered with ovulation in seven of eight mares [108]. 
Although there is evidence of success using dexamethasone, a survey from 2007 reflects 
that using glucocorticoids was not a preferred option for veterinarians attempting to 
suppress estrus in mares [109].  
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11.  Prolonging CL Function as a Method of Estrus Suppression 
 
11.1  Induction of Late-Diestrus Ovulation 
 In contrast to most other species, mares can ovulate new follicles while being in a 
state of diestrus. This can occur as a spontaneous phenomenon or be influenced by an 
ovulation induction agent. Spontaneous mid or late diestrus ovulations may result in 
prolonged CL activity and maintain elevated progesterone through the point of luteolysis. 
This resistance to PGF2α is most likely because the CL deriving from the diestrus follicle 
is not mature enough to be susceptible to the luteolytic hormone [110]. In an evaluation 
of breed prevalence, this phenomenon of diestrus ovulation occurs in about 20% of 
Thoroughbreds and Quarter Horses during diestrus, yet is very unlikely in pony mares 
[45,111].  
 Using ovulation induction agents such as human chorionic gonadotropin (hCG), 
it is possible to induce large diestrus follicles (suggested follicles ≥ 35 mm in diameter) 
to ovulate even in the presence of high concentrations of progesterone. A 2006 study by 
Hedberg et al. indicated that the ovulation of diestrus follicles was a possible therapeutic 
tool for estrous suppression by prolonging luteal activity [112]. Five mares were 
evaluated during diestrus using transrectal palpation and ultrasonography for a diestrus 
follicle ≥ 30 mm. When an appropriate sized follicle was detected, 3000 IU of hCG was 
administered as to induce ovulation. Three of the five mares evaluated successfully 
exhibited prolonged luteal activity, one mare was treated with hCG but did not ovulate 
the diestrus follicle, and the fifth mare never developed a diestrus follicle large enough to 
administer the hCG treatment. 
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 The induction of late-diestrus ovulation is a viable treatment option for estrus 
suppression, but is not an optimal choice for most horse owners. The need for repeated 
transrectal examinations and the chance that the mare may never develop a diestrus 
follicle large enough to treat leaves a chance that the owner will just be wasting time and 
money.  
 
11.2  Intrauterine Marbles 
Sterile glass marbles ranging from 25 mm to 35 mm placed into the uterine lumen 
have been used to suppress estrus in mares. These marbles are inserted following 
ovulation and are assumed to mimic the presence of a conceptus in the uterus. The 
previous understanding was that the marble impeded the ability of the endometrium to 
secrete PGF2α by its mobility throughout the uterus mimicking a conceptus or that the 
marble mildly damaged the endometrium impairing its ability to maintain the luteolytic 
mechanism. It has recently been shown that other types of intrauterine devices (IUD) in 
mares inhibit the upregulation of COX-2, which could also be an effect that intrauterine 
marbles may have on the endometrium. The use of a sterile glass marble for estrus 
suppression is past its prime as veterinarians have concluded that negative consequences 
outweigh the benefits [113]. The efficacy rate to prolong CL function (approximately 
35%) using intrauterine marbles is fairly low compared to other estrus suppression 
therapies [8]. In some cases, the marble may pass back through the cervix and be 
expelled immediately, or could be expelled the next time the mare enters estrus and her 
cervix is relaxed. There have been reports of glass marbles shattering inside the mare’s 
uterus. This is most often caused by placement of a second marble without the removal of 
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the initial marble. The use of intrauterine marbles also has other associated side effects 
that have been clinically documented including colic-like symptoms and pyometra 
[114,115].  
 
11.3  Other Intrauterine Devices 
 Research on proprietary IUD methods of estrus suppression has been pursued as 
the need for an alternative to an intrauterine marble has become apparent. These 
proprietary units range in size and structure, as well as materials. In a study by Rivera Del 
Alamo et al., a 20 mm water filled polypropylene ball was deposited in the uterus of 
mares on day 3 post-ovulation. Thirteen of 15 treated mares exhibited prolonged luteal 
function and it was determined that the abundance of COX-2 was decreased in non-
pregnant mares treated with the IUD [77]. More recently, a self-assembling IUD (Upod) 
has been analyzed. The Upod is a set of three polymer-coated elliptically shaped 
magnetic units which self-assemble into a “ring” conformation when deposited into the 
uterus of the mare. In the first experiment in which the Upod was deposited into the mare 
during estrus 13 of 15 mares exhibited prolonged luteal activity with the average length 
extending to 73.4 days [116]. A second experiment in the same report resulted in 12 of 14 
mares exhibiting prolonged luteal activity for an average length of 51.3 days when the 
Upod was deposited in the mare at a random point of the estrous cycle. Although all 
mares in the study retained the Upod, there was an elevated level of endometritis. IUDs 
have many applications for estrus suppression and synchronization, but the potential for 




11.4  Intrauterine Infusion of Plant Oils 
In a 2011 study, Wilsher and Allen demonstrated that a single intrauterine 
infusion of 10 mg of slow-release estradiol in fractionated coconut oil was an effective 
method of prolonging CL function in mares [117]. With treatment administration on day 
6, 8, 10, 12, and 14 post-ovulation prolonged CL function was observed in 25%, 75%, 
92%, 83%, and 50% of mares, respectively. The intrauterine infusion of plant oils on day 
10 post-ovulation showed similar results when either coconut oil or peanut oil was 
administered alone (92% for each), indicating that estradiol was not necessary to induce 
luteostasis in mares. There is a need for further research on the intrauterine infusion of 
plant oil to uncover if this technique modulates prostaglandin production or secretion. It 
is hypothesized that the assortment of fatty acids found in both coconut and peanut oils is 
the underlying factor contributing to prolonged CL function using these techniques.   
 
12.  Immunologic Methods of Estrus Suppression 
GnRH stimulates the pituitary gland to release LH and FSH causing follicular 
growth and eventual ovulation. Removing this stimulus for gonadotropin secretion 
reduces or halts ovarian activity which stops estrogen secretion and ultimately nullifies 
estrous behavior. The commercial GnRH vaccine known as Equity (manufactured by 
Zoetis) is not currently available and has never been FDA approved. This vaccine acts to 
create antibodies against GnRH making it impossible for the endogenous GnRH to act on 
its receptors at the pituitary gland. Equity was previously available in Australia, but has 
since been removed from Zoetis’ lineup of products. When treated with this vaccine, 
some mares still continued to display estrous behavior despite the lack of ovarian activity, 
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which, as noted previously, is referred to as paradoxical estrous behavior. Aged mares 
may require repeated vaccination for treatment to be efficacious. Most mares treated had 
extremely long periods of inactive ovarian function while some mares never regained any 
ovarian activity [118]. There is no reversal to a GnRH vaccination which is a major 
disadvantage to this method of estrus suppression.   
 
13.  Surgical Methods of Estrus Suppression 
 One of the most puzzling phenomena in mare reproduction revolves around the 
surgical removal of the ovaries. This remedy to resolve issues associated with estrus 
behavior is, in theory, a “cure” to all deleterious reproductive behavior. Although the 
ovaries are the major control center for the behavior associated with the estrous cycle and 
house follicles that produce estrogen, mares that have undergone an ovariectomy may 
still exhibit estrus-like behavior. This phenomenon is supported by hormone secretion 
from the adrenal cortex and is referred to as “paradoxical” estrous [119]. Ovariectomy is 
viewed as a last resort for the management of estrus behaviors due to the limitation this 
surgical method places on the future reproductive capacity of the mare and marginal 
efficacy.  
 Assessing a mare’s behavior during winter anestrous may be the best clinical 
evaluation to determine if an ovariectomy can be helpful. During this time, the behavior 
of the mare can be evaluated while ovarian activity is minimized or absent. However, 
mare physiology is complex and not always consistent. During the winter months 
consisting of short days, some mares (10-15%) continue their estrous cycles and do not 
become anovulatory. In this case, it is possible the mare is exhibiting deleterious behavior 
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associated with a true state of estrus even during the anovulatory period of the year. If a 
mare’s behavior is evaluated during the winter anovulatory phase and “bad” behaviors 
are still present, ovariectomy may consequentially make the mare’s behavior worse. It is 
often misconstrued that exogenous progestin treatment will have the same effect as 
ovariectomy. This is not the case as the ovaries house the primary source of endogenous 
progesterone, and removing one hormone is not the same as adding a different one. A 
veterinarian may gain more insight by using hormonal analysis of progesterone and 
estrogen to determine a direct association between ovarian activity and mare behavior.   
 
14.  Pregnancy as a Method of Estrus Suppression 
Pregnancy is the most common reason for prolonged CL function. To achieve 
luteostasis associated with pregnancy multiple events must occur. The mare must be 
mounted by a stallion and undergo successful copulation or be bred by artificial 
insemination (AI) resulting in a fertilized oocyte to undergo embryonic development. The 
embryo must successfully pass from the oviduct into the uterine lumen and remain 
mobile in the uterus, contacting the majority of the endometrial surface. The mobility of 
the embryo in combination with the secretion of a currently unknown substance disrupts 
the luteolytic pathway of the mare to prolong the function of the primary CL [87].   
In the efforts of estrus suppression, it is possible to manually rupture the 
established conceptus by transrectal manipulation. In a study by Lefranc and Allen using 
11 mares, all mares displayed CL function beyond 60 days post-ovulation when the 
embryo was manually reduced between 16 and 22 days post-ovulation [120]. It is also 
possible to abort a foal between 50 and 60 days of gestation and maintain elevated 
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progesterone concentrations for over 120 days post-ovulation. At this later point in 
gestation the mare has developed endometrial cups, which will effectively inhibit the 
mare from returning to estrus for approximately 60 days. Aborting a foal at a later point 
in gestation is much more difficult than manually reducing an early conceptus. Pregnancy 
as an effort to accomplish estrus suppression is not fully successful, as a small number of 
mares will show signs of estrous even while pregnant [109].  
With the manual reduction of a conceptus and clinical abortion of a foal there are 
also undesirable implications. The cost of getting a mare pregnant and the ethics involved 
in terminating a healthy pregnancy may be objectionable to some horse owners [121].  
 
15.  Oxytocin Induced Luteal Maintenance 
 In the on-going effort to suppress estrus behavior in the mare, there have been 
many changes in the clinical “gold standard.” All of the previously discussed methods 
have their individual benefits and deleterious consequences. Further research of estrous 
suppression techniques is essential to provide a reliable and applicable treatment 
protocol. The use of oxytocin to suppress estrus behavior in mares is gaining use among 
veterinarians as a clinical therapy to prolong CL function for the purposes of estrus 
suppression. Oxytocin is most often thought of as a catalyst of the luteolytic pathway that 
eliminates function of the CL, but can also be exogenously administered to disrupt the 
upregulation of COX-2 and prolong CL function. Spontaneously prolonged CL function 
has been observed in about 10% of cycling mares and has an average duration of 63 ± 
15.6 (SD) days [15]. Oxytocin is relatively inexpensive and can be delivered 
intramuscularly in an aqueous solution. The use of oxytocin also provides a method of 
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estrus suppression that does not require the use of exogenous steroid hormones, which is 
a concern to some regarding performance horses [9]. 
 
15.1  Early Oxytocin Discoveries 
 In a 1987 study, Goff et al. identified the ability of exogenous oxytocin to prolong 
luteal function in mares. Four non-pregnant mares were administered oxytocin IV (10 
IU/500 kg) daily from days 9 through 14 post-ovulation, and again on days 16, 18, and 
20. Indicated by progesterone concentrations staying above 4 ng/ml for the remainder of 
the study, none of the treated mares returned to estrus by 22 days post-ovulation [79].  In 
a 1999 study, Stout et al. hypothesized that oxytocin was integral to luteolysis and 
determined if continuous systemic administration of oxytocin in cycling mares delayed 
luteolysis [31]. They approached this study by implanting subcutaneous osmotic 
minipumps filled with a solution of oxytocin in the neck of 10 mares. The pumps were 
inserted into five mares on day 8 post-ovulation and five mares on day 10 post-ovulation 
and delivered oxytocin at a rate of 5 μl/h. The osmotic minipumps were maintained in the 
mares for 12 days while mares were transrectally palpated and scanned using 
ultrasonography. Blood samples were collected from the mares and serum progesterone 
concentrations were evaluated for determination of CL function. The results indicated 
that four of five mares administered the minipump on day 8 post-ovulation and three of 
five mares administered the minipump on day 10 post-ovulation maintained elevated 
serum progesterone concentrations. In the group of mares administered the minipump on 
day 10 post-ovulation, both mares that failed to develop prolonged luteal function 
underwent premature luteolysis. This hastened luteolytic event is a good example of the 
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dual-functionality of oxytocin at the level of the endometrium. Exogenous oxytocin 
administration in early diestrus can work to inhibit the luteolytic process. Alternatively, 
exogenous administration or endogenous pulses of oxytocin in mid to late diestrus (on or 
after day 10) may trigger the luteolytic process. The transition from anti-luteolytic to pro-
luteolytic roles of oxytocin will be discussed in more detail later in this review. In 
correlation to the maintenance of progesterone concentrations, the primary CL remained 
observable through ultrasonographic evaluation.  
 This research on the role of oxytocin in luteolysis helped open the door of 
exploration into oxytocin as a method of estrus suppression.  
 
15.2 Twice-Daily vs Once-Daily Oxytocin  
 Administration 
To develop an oxytocin treatment protocol to prolong CL function, Vanderwall et 
al. treated six mares twice daily with 60 IU of oxytocin IM from days 7 through 14 [122]. 
Treated mares were compared to a saline treated control group to determine if luteolysis 
would be averted and evaluate the prolonged function of the CL. All six of the mares 
treated with oxytocin exhibited elevated progesterone concentrations above 1 ng/ml 
continuously through day 30 while none of the control mares displayed prolonged luteal 
function. 
In a follow up study, once and twice daily IM administration of 60 IU of oxytocin 
were compared [10]. Eight mares were administered oxytocin once daily and seven mares 
were treated twice daily from day 7 through 14 post-ovulation. In addition, seven 
untreated control mares were used to account for spontaneous prolonged luteal function. 
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It was determined that there was not a significant difference in the treatment protocols 
with five of eight (63%) mares treated once daily and five of seven (71%) mares treated 
twice daily having prolonged CL function. In the control group, one of seven (14%) 
mares exhibited spontaneous prolonged luteal function. This study determined that once 
daily administration was equally efficacious to twice daily administration of oxytocin. A 
subsequent study showed that once daily administration becomes more efficacious with 
longer durations of treatment. Keith et al. treated groups of seven mares from day 8 to 10, 
8 to 12, and 8 to 14, with 60 IU oxytocin IM daily and observed 43%, 57%, and 86% 
prolonged CL function indicating that in order to achieve an optimal effect, the oxytocin 
treatment must be continued until day 14 after ovulation [13].  
 
15.3  Chronic Oxytocin Administration 
 Most estrus suppression oxytocin therapies require knowledge of the specific 
point of the estrous cycle that the mare is in. This is determined by repeated transrectal 
examination by a veterinarian using palpation and ultrasonography. The cost of repeated 
transrectal examinations can be a major drawback to mare owners. The chronic 
administration of oxytocin is an available solution to the owners wanting to avoid these 
repeated examinations. Parkinson et al. demonstrated that daily IM administration of 60 
IU of oxytocin continued for 29 days can effectively prolong CL function [11]. Seven of 
nine mares had prolonged CL function when treatment was initiated at a random point in 
the estrous cycle. It was determined that three of the seven mares with prolonged CL 
function first underwent luteolysis before developing prolonged CL function following 
the subsequent ovulation. The Parkinson et al. study of chronic administration of 
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oxytocin clearly demonstrated the luteolytic and antiluteolytic effects of oxytocin. When 
treatment was initiated during late diestrus the endometrium was prepared to trigger the 
luteolytic process. Oxytocin at this time point interacts with the uterus by stimulating the 
cyclooxygenase pathway of prostaglandin synthesis. This pathway results in the 
production of PGF2α, which is the key hormone in luteolysis, and stops the CL from 
producing progesterone. Alternatively, when treatment was initiated earlier in diestrus the 
endometrium of the mare was unable to fulfill the luteolytic process. The inability to 
synthesize PGF2α was continued as the oxytocin treatment inhibited the upregulation of 
COX-2, an important synthetic enzyme in the cyclooxygenase pathway. The physiology 
of prolonging CL function using oxytocin treatment will be discussed in more detail later 
in this review. The anti-luteolytic and pro-luteolytic functions of oxytocin are extremely 
important to understand in the development of new treatment protocols and 
pharmacological development of oxytocin analogs. Successful chronic oxytocin 
administration intended to prolong luteal activity may work through one or both functions 
of oxytocin depending on the phase of the mare’s estrous cycle. 
 
15.4  Proprietary Slow-Release Oxytocin 
 Although the above-mentioned oxytocin protocols are effective, the requirement 
for daily administration is a limitation to their clinical application. With a half-life of 6.5 
minutes, the pharmacological characteristics of oxytocin also pose a challenge in the 
development of a therapeutic regimen that does not require daily administration. 
Proprietary slow-release oxytocin (SR-OT) formulations have been explored in pilot 
studies and will be expounded upon in the research associated with this review. In a 2018 
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preliminary study, three different SR-OT formulations from SR Veterinary Technologies 
(Windsor, CO) were compared. Two of the slow-release formulations were administered 
only once on day 7 and the third formulation was administered once on day 7 and again 
on day 10. The third formulation, with administration on day 7 and 10 yielded the 
greatest efficacy with five of six mares treated having prolonged CL function [12]. All 
pilot study preparations contained 2,400 IU/ mL and were administered in one mL doses. 
It was determined that more research must be conducted to validate the efficacy of this 
proprietary formulation and protocol in comparison to a control group which is discussed 
in the research associated with this review. 
 
15.5  Oxytocin Administration Indicated by Behavior 
 The limitations of repeated examinations to determine estrous cycle status pose a 
financial and time-consuming barrier in front of most oxytocin therapies. To avoid 
transrectal examination, a mare can be evaluated for estrus and diestrus behaviors to time 
the initiation of treatment. In a study by Manning et al. 54.5% of mares had prolonged 
CL function when 60 IU of oxytocin was administered IM on day 8 through 17 after the 
first day the mare showed behavioral estrus when teased to a stallion [123]. Although this 
study indicated efficacy at a lower rate compared to protocols using transrectal ultrasound 
and palpation (70-75%), it shows that it is possible to avoid the costs associated with 
veterinary examinations. 
 
15.6  Oxytocin Analogs 
 Carbetocin, an oxytocin analog, was hypothesized to have a similar effect to 
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oxytocin in attempts to prolong CL function. Carbetocin has a half-life almost triple that 
of aqueous oxytocin (17.2 minutes in comparison to 6.8 minutes) [124,125]. The efficacy 
of carbetocin (1.19 mg) was compared to oxytocin (60 IU) in a 2013 study by Bare et al. 
Both treatments were administered IM from day 7 to 14 post-ovulation, but the 
carbetocin treatment significantly abbreviated the IOI rather than lengthening it [126]. An 
interesting note to add from the study by Bare et al. is that neither treatment (carbetocin 
or oxytocin) was reported to inhibit estrous behavior when mares were exposed to a 
mature stallion. 
 
16.  Physiology of Prolonging CL Function 
 Understanding the physiology of prolonging CL function has been a puzzling 
research task. There are many pieces to the process of luteolysis which are all necessary 
for successful termination of luteal funtion. The methods described above which prolong 
luteal activity all disrupt luteolysis at one point or another. It has been hypothesized that 
the downregulation of oxytocin receptors, the inability for the endometrium to synthesize 
prostaglandin, or the inability for the endometrium to secrete prostaglandins. Recent 
studies have shown that oxytocin therapies as well as IUD therapies inhibit the 
upregulation of COX-2 in order to disrupt the luteolytic pathway [13, 77].  
COX-2 is a catalytic enzyme which influences the synthesis of PGH2 from AA, 
after which PGH2 is subsequently converted into multiple prostaglandins including 
PGF2α. In cattle, bovine interferon-tau associated with pregnancy also causes the down-
regulation of COX-2 and prostaglandin F synthase expression [92]. Pregnancy in mares 
also inhibits COX-2 expression [77]. It is known that pregnancy delays the upregulation 
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of oxytocin receptor expression and that the conceptus plays a role in reducing the 
number oxytocin receptors expressed [76,82]. The use of oxytocin to prolong CL 
function has been hypothesized to inhibit oxytocin receptor expression as well. This 
hypothesis was disproved by Vanderwall et al. as oxytocin-binding capacity on day 15 
post-ovulation was not significantly different in normal cycling mares in comparison to 
mares treated with 60 IU oxytocin IM twice daily from day 7 to 14 post-ovulation [10]. 
The specific mechanism by which oxytocin or IUD therapies disrupt COX-2 has not been 
determined. To further understand the mechanism by which these techniques inhibit 
luteolysis it may be helpful to look at the steps previous to COX-2 in the luteolytic 
pathway. Rivera et al. hypothesized that PLA2, which is required for releasing AA from 
membrane cells, could initially be obstructed by an IUD [77].  
 Reports have indicated that IUD techniques can be administered at any point in 
the estrous cycle and exhibit successful disruption of luteolysis [116]. The same cannot 
be said for oxytocin therapies in which only the chronic administration of aqueous 
oxytocin has shown to be efficacious when it was initiated at any time point of the estrous 
cycle [11]. In order to properly time other oxytocin protocols, it is important to 
understand that oxytocin plays a role in luteolysis during late diestrus [50]. To avoid the 
luteolytic effect of oxytocin, treatment must be administered before day 10 post-
ovulation. As mentioned previously, treatment must not only be initiated before day 10, 
but must be continued until day 14 to increase efficacy and inhibit COX-2 [13]. In a 2013 
study, Keith et al. researched many aspects of oxytocin treatment to prolong luteal 
function [13]. Their first experiment demonstrated the necessity of oxytocin treatment 
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beyond day 10 post-ovulation to successfully prolong CL function. Three of seven, four 
of seven, and six of seven mares exhibited prolonged luteal activity after daily 
intramuscular oxytocin administration of 60 IU on days 8 to 10, 8 to 12, and 8 to 14 post-
ovulation, respectively. In a second experiment from the same publication, day 14 uterine 
biopsies from mares treated with oxytocin from days 8 to 14 were compared to day 14 
uterine biopsies from saline-treated control mares. The uterine biopsies were evaluated 
for prostaglandin synthetic enzyme expression, as well as oxytocin and estrogen receptor 
expression. Keith et al. found that mares treated with oxytocin expressed a significantly 
lower amount (p < .01) of COX-2 than the control mares with a 3.7-fold decrease in 
oxytocin-treated mares. It was also determined that there was no significant difference in 
PGFS, estrogen receptor, or oxytocin receptor expression between the oxytocin-treated 
mares and control mares. This study by Keith et al. provided information vital to the 
understanding of oxytocin techniques to prolong luteal activity and was influential on the 
research associated with this review. 
 The similarities between pregnancy and therapeutically prolonged CL function 
provoke interest into their comparative research. Of course, one of the greatest puzzles of 
all animal science is the complexity of maternal recognition of pregnancy in the mare. 
The physiological understanding of estrus suppression therapies may give clues towards 





EVALUATION OF A PROPRIETARY SLOW-RELEASE OXYTOCIN 
FORMULATION ON CORPUS LUTEUM FUNCTION IN MARES1 
 
ABSTRACT 
Prolonging function of the corpus luteum (CL) is a method of suppressing estrus 
that relies on continued secretion of endogenous progesterone to keep mares out of heat 
naturally.  The use of oxytocin treatment to prolong CL function is gaining increasing 
use, and the most common treatment protocol involves administration of 60 units of 
oxytocin intramuscularly (IM) once daily on days 7 to 14 after ovulation (8 daily 
treatments).  Although that protocol induces prolonged CL function in ≥70% of treated 
mares, the need for daily administration is a drawback to its use.  Therefore, the objective 
of this study was to evaluate the efficacy of a proprietary slow-release oxytocin 
formulation (SR-OT) for prolonging CL function that requires only two treatments.  
Mares were examined via transrectal palpation and ultrasonography to determine the day 
of ovulation (day 0) and then randomly assigned to a non-treated control group and an 
SR-OT treatment group (n = 8 mares/group).  Mares in the treated group received 1.0 mL 
of SR-OT containing 2,400 IU oxytocin IM once on Day 7 and again on Day 10 after 
ovulation.  Jugular blood samples were collected on day 0 and then every M, W and F for 
50 days for determination of the serum progesterone concentration.  Mares were 
classified as having prolonged CL function if their progesterone concentration remained 
                                                          
1 Contributing authors: B. A. Sarnecky, D. K. Vanderwall, H. M. Mason (Utah State University), S. M. 
Kirschner (Wildlife Pharmaceuticals, Windsor, CO), B. Ambrose, & T. L. Parker (Utah State University). 
Reprinted in this thesis with permission of all authors and Journal of Equine Veterinary Science, 77, 28-30. 
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>1.0 ng/mL continuously for at least 30 days.  Corpus luteum function was prolonged in 
0/8 (0%) control mares and 6/8 (75%) of the SR-OT-treated mares (p < 0.01).  The 
demonstrated efficacy of this two-injection, SR-OT protocol represents a 75% reduction 
in the number of oxytocin treatments compared to daily administration of oxytocin from 
Day 7 to 14, making it a more practical treatment protocol. 
 
1. Introduction 
Suppression of estrous behavior is a common management strategy implemented 
in mares. Various methods to suppress estrous behavior are used to mitigate real and/or 
perceived negative effects of the behavior on performance activities such as showing and 
racing [1]. Although daily administration of the FDA-approved, orally-active, synthetic 
progestin altrenogest is efficacious and has been widely used for suppressing estrous 
behavior in mares, the expense, need for long-term daily administration, and safety risks 
for personnel during handling have collectively led to the increased use of alternative 
methods of suppressing estrus [5]. For the past 15 years, placement of an intrauterine 
glass ball has been the most common method of prolonging corpus luteum (CL) function 
[8]. However, the use of intrauterine glass balls has been called into question due to 
numerous reports of severe complications associated with their use [7]. Prolonging the 
functional lifespan of the CL using exogenous oxytocin therapy is a simple and cost-
effective method of suppressing estrus that has gained increased use in clinical practice. 
This method capitalizes on continued natural secretion of progesterone from the CL to 
eliminate estrous behavior [121]. Sustaining the CL using oxytocin to inhibit luteolysis 
has been proven effective by two different methods [9]. If the day of ovulation is known, 
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60 IU of oxytocin can be administered intramuscularly (IM) on days 7 through 14 after 
ovulation. If the day of ovulation is unknown, 60 IU of oxytocin can be administered IM 
for 29 consecutive days. Although both protocols provide equivalent efficacy, with an 
induced rate of prolonged CL function of approximately 70%, the need for daily 
administration is a limitation to this method of estrus suppression.  
In an effort to eliminate the need for daily administration of oxytocin, the use of 
proprietary slow-release oxytocin (SR-OT) formulations have been investigated for 
prolonging CL function. Based upon the results of a previous study [12], it was 
hypothesized that a two-injection SR-OT protocol would deliver an appropriate amount 
of oxytocin for a sufficient duration of time to inhibit luteolysis. The previous study 
compared the efficacy of three proprietary SR-OT formulations for prolonging CL 
function [12]. Of the three formulations tested, one appeared to be suitably efficacious, 
since it prolonged CL function in 83% of the treated mares. This particular formulation 
involved administration of 2,400 IU oxytocin IM once on day 7 and again on day 10 after 
ovulation.  However, that formulation was not directly compared to a control group of 
mares. Therefore, the objective of this study was to determine if IM administration of 
2,400 IU of SR-OT once on days 7 and 10 after ovulation would prolong CL function in 
treated mares compared to a non-treated control group.  
 
2. Materials and Methods 
2.1. Animal Care and Use 
All animal procedures were approved and conducted following the guidelines of 
the Utah State University Institutional Animal Care and Use Committee (Protocol 
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#2853). This study used 16 American Quarter Horse-type mares ranging from 3 to 18 
years of age with known reproductive and health histories. Each mare used in this study 
was evaluated and determined to have a normal estrous cycle prior to inclusion in the 
study. 
 
2.2. Experimental Protocol 
Between May and July in the Northern Hemisphere (41.7° N) cycling mares were 
examined using transrectal palpation and ultrasonography. Mares with an ovarian follicle 
≥ 30 mm in diameter and prominent endometrial edema were examined daily until 
ovulation (day 0) was detected. Ovulation was determined by the disappearance of a 
follicle > 35 mm in diameter with the resulting CL being observed by transrectal 
ultrasonography. Following ovulation, mares were randomly assigned to a non-treated 
control group (n = 8) and an SR-OT treatment group (n = 8).  SR-OT mares received 1.0 
mL (2,400 IU) of a proprietary SR-OT formulation (SR Veterinary Technologies, 
Windsor, Colorado 80550) IM once on day 7 and once on day 10 post-ovulation.  
 
2.3. Blood Collection 
Using red-top blood collection tubes with no anti-coagulant, blood samples from 
the jugular vein were collected on day 0 and then every Monday, Wednesday, and Friday 
through and including day 50. Blood samples were allowed to clot at room temperature 
before being centrifuged at 125 × g for 20 minutes at 21° C. Serum was recovered from 




2.4. Progesterone Assay 
Serum samples were processed and evaluated for progesterone concentration by a 
commercially available kit (Immulite Progesterone, Siemens, Malvern, PA, USA) 
according to the manufacturer’s instructions. The sensitivity of this assay was 0.2 ng/mL.  
Intra- and inter-assay coefficients of variation were 21.2% and 19.8%, respectively.  
Mares with serum progesterone levels that remained > 1.0 ng/mL for at least 30 days 
were considered to have prolonged CL function.  
 
2.5. Statistical Analysis 
The proportion of mares with prolonged CL function in each group was compared 
using Fisher’s Exact Test (GraphPad Software, Inc., La Jolla, CA, 92037). A value of p < 
0.05 was considered significant.  
 
3. Results 
Corpus luteum function was prolonged in 0/8 (0%) non-treated control mares and 
6/8 (75%) of SR-OT treated mares (Fig. 6; p < 0.01). 
 
4. Discussion 
Oxytocin has opposing effects at different stages of the estrous cycle. In late 
diestrus (after day 10), oxytocin (endogenous or exogenous) has a “pro-luteolytic” effect 
that stimulates prostaglandin-F2α (PGF2α) secretion from the endometrium. Luteolysis 
occurs during late diestrus as a result of endogenous pulsatile oxytocin secretion from the 
posterior pituitary gland that is associated with pulsatile secretion of uterine PGF2α [68, 




Fig. 6. Progesterone concentration profiles of non-treated control mares and mares 
treated with a proprietary slow-release oxytocin (SR-OT) formulation. (A) Serum 
progesterone concentrations in 8 non-treated control mares. (B) Serum progesterone 
concentrations in 8 mares treated intramuscularly with 1.0 mL of a proprietary SR-OT 
formulation containing 2,400 IU on days 7 and 10 after ovulation. For clarity, lines are 
truncated after luteolysis in mares that did not have prolonged CL function. All mares 
that underwent luteolysis did so before 18 days post-ovulation. A threshold for 
progesterone concentration, indicating continued CL function, is marked at 1.0 ng/mL. 
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continues through positive feedback mechanisms involving PGF2α to stimulate posterior 
pituitary release of oxytocin [128]. Prior to day 10 after ovulation, therapeutic treatment 
with oxytocin has an “anti-luteolytic” effect as it inhibits the upregulation of the key 
synthetic enzyme necessary for PGF2α production, cyclooxygenase-2 (COX-2) [13,129]. 
Whether the instigating factor is therapeutic or idiopathic, the functional life span of the 
CL in the absence of a luteolytic event is approximately 2 to 3 months [15]. Although 
spontaneously prolonged luteal function did not occur in any of the control mares of this 
study, this event can occur in up to 10% of mares during the breeding season and 25% of 
mares in the fall transition [33,36]. This idiopathic phenomenon of spontaneously 
prolonged luteal function highlights the need for an appropriate group of control mares 
when evaluating the effect of any treatment on luteal function. 
Therapeutically prolonging the functional lifespan of the CL in mares using 
oxytocin to inhibit luteolysis has proven to be an effective method of estrus suppression 
that provides an alternative to daily administration of oral progestins (e.g., altrenogest) [9, 
121]. It is assumed that SR-OT has a short-term continuous effect similar in function to 
the previously mentioned 8-day protocol (days 7 through 14) in the manner that it 
occupies oxytocin receptors at the endometrial epithelium and inhibits upregulation of 
COX-2. In a study by Keith et. al. comparing daily administration of 60 IU of aqueous 
oxytocin IM on days 8 to 10, 8 to 12, and 8 to 14, the proportion of mares with prolonged 
luteal function increased significantly as the duration of treatment increased [13]. 
Therefore, continuation of oxytocin treatment beyond day 12 after ovulation is required 
to attain maximum efficacy in the inhibition of upregulation of COX-2 [13]. The efficacy 
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of SR-OT administered once on day 7 and again on day 10 demonstrates that there was a 
sufficient amount of oxytocin present to inhibit the upregulation of COX-2. Therefore, 
delivery of oxytocin via administration of SR-OT on days 7 and 10 had an effect 
equivalent to the daily administration of aqueous oxytocin on days 7 to 14. 
The present results imply that SR-OT treatment delivers oxytocin at an 
appropriate therapeutic level from day 7 through 10, and again from day 10 through 13, 
resulting in an optimal anti-luteolytic effect without having pro-luteolytic consequences. 
The same is not true for the long-acting oxytocin analogue carbetocin. Carbetocin has a 
half-life of 17.2 minutes, in comparison to the 6.8-minute half-life of aqueous oxytocin 
[124,125]. In a study comparing the efficacy of carbetocin (1.19 mg) compared to 
aqueous oxytocin (60 IU) both administered IM daily from days 7 to 14, carbetocin 
significantly shortened the inter-ovulatory interval [126]. The lack of carbetocin efficacy 
contrasted by the successful inhibition of luteolysis with SR-OT in the present study 
implies that SR-OT delivered enough oxytocin to inhibit luteolysis, without triggering 
pro-luteolytic effects. 
In conclusion, IM administration of SR-OT containing 2,400 IU oxytocin on days 
7 and 10 after ovulation was reliably efficacious for prolonging the functional lifespan of 
the CL in mares.  Therefore, this new treatment protocol is equally effective when 
compared to the previously established eight-injection protocol using daily oxytocin 
treatments on days 7 to 14 after ovulation [10].  Importantly, this two-injection oxytocin 





OXYTOCIN INDUCED SECRETION OF 13,14-DIHYDRO-15-KETO 
PROSTRAGLANDIN F2α (PGFM) IN MARES WITH PROLONGED  
CORPUS LUTEUM (CL) FUNCTION2 
 
ABSTRACT 
Therapies using hormonal or physical stimuli to prolong CL function have gained 
popularity as tools for estrus suppression in performance mares. Previous studies have 
shown that the endometrium of mares having been treated with either oxytocin or an 
intrauterine device (IUD) as methods to prolong CL function disrupt the synthesis and 
secretion of prostaglandin F2α (PGF2α). In these therapies, upregulation of 
cyclooxygenase-2 is inhibited and impairs PGF2α production. This study evaluated the 
ability of the endometrium to synthesize and secrete PGF2α in mares with 
therapeutically-induced prolonged CL function. After ovulation (day 0), CL function was 
evaluated using progesterone concentrations in venous blood samples. Prolonged CL 
function was induced using oxytocin treatment, after which mares were assigned to 
groups 50-59 days, 60-69 days, or 70-79 days (50s, 60s, or 70s) post-ovulation. For 
comparison, a 14-day post-ovulation control group was used. The ability of the 
endometrium to synthesize PGF2α was evaluated by measurement of 13,14-dihydro-15-
keto PGF2α (PGFM) in response to a single 10 IU intravenous oxytocin bolus (time 0). 
Blood samples were collected at -30, -15, 0, 5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 105, and 
                                                          
2 Contributing authors: B. A. Sarnecky, D. K. Vanderwall, H. M. Mason, C. C. Reichhardt, & B. Ambrose 
(Utah State University). Reprinted in this thesis with permission of all authors. Unpublished manuscript, 
Utah State University, Logan, UT. 
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120 minutes. The area under the curve was significantly higher in the 70s group 
compared to the 50s and 60s groups (p< 0.001; p< 0.02, respectively). There was no 
significant difference between the 70s group and the control group (P>0.36). The 
progesterone concentration curves are consistent with these findings as CL function was 
maintained after the oxytocin bolus in 4 of 4 mares in the 50s, 3 of 4 mares in the 60s, 
and 0 of 3 mares in the 70s group. These results revealed a clear shift in the endometrial 
environment of the mare between 50 and 70 days after ovulation concerning the ability to 
synthesize PGF2α during the period of prolonged CL function. 
 
1.  Introduction 
Endogenous oxytocin in the mare is a primary stimulus that provokes the synthesis 
and secretion of the luteolytic hormone prostaglandin F2α (PGF2α) from the 
endometrium.  Exogenous oxytocin, alternatively, can be therapeutically administered for 
both luteolytic and anti-luteolytic functions depending on the phase and timing of the 
mare estrous cycle when it is administered [79,121]. At the writing of this article, it has 
been known for over 20 years that oxytocin can therapeutically prolong corpus luteum 
(CL) function in cycling mares [31]. The clinical use of oxytocin to inhibit luteolysis has 
gained popularity as an alternative estrus suppression therapy because of the simple and 
cost-effective treatment protocols that are more efficacious and safer than previous 
methods to prolong CL function (i.e., intrauterine glass balls) [7].  
Luteolysis is a critical point in the mare estrous cycle at which progesterone 
concentrations corresponding to the function of the CL decrease to less than 1.0 ng/mL 
[15]. Complete luteolysis in the mare involves many pulses of endometrial derived 
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PGF2α preceded by pulses of oxytocin originating from the posterior pituitary gland over 
a 23-hour period [53]. Oxytocin interacts with its receptors at the endometrium to 
stimulate luteolytic surges of PGF2α targeting the CL through systemic circulation [130]. 
The state of prolonged CL function in the mare is described as progesterone 
concentrations greater than 1.0 ng/mL for more than 30 days post-ovulation. In a state of 
prolonged luteal activity, the average duration of CL function is 63 days (SD ± 15.6 
days) [15]. Two protocols using exogenous oxytocin have been described for prolonging 
CL function. One protocol involves administering 60 IU of oxytocin intramuscularly 
(IM) once daily on days 7 through 14 after ovulation [10]. The second protocol can be 
initiated at any point in the estrous cycle and involves daily administration of 60 IU of 
oxytocin IM for 29 consecutive days [11]. Both of these protocols are equally effective 
and prolong CL function in about 70% of treated mares.  
In an effort to extend the average length of prolonged CL function using oxytocin 
treatment, the addition of human chorionic gonadotropin (hCG) to oxytocin treatment has 
been studied. In an experiment by Vanderwall et al., mares were first treated with 60 IU 
of oxytocin IM to prolong CL function on days 7 through 14 after ovulation [14]. It was 
hypothesized that hCG, administered on days 30, 45, 60, 75, and 90 would have a 
luteotrophic effect, or induce the ovulation of a diestrus follicle. It was thought that a 
diestrus ovulation would reset the length of prolonged CL function and the new CL 
formed from the ovulatory transition of the diestrus follicle would persist for an 
additional 65 days. The results indicated that there was no significant difference in the 
length of luteal function between mares that were treated with oxytocin to prolong luteal 
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function and mares that received hCG in addition to oxytocin treatment. Upon further 
evaluation of the records, it was apparent that even when a diestrus ovulation resulted in a 
functional CL, the duration of elevated progesterone concentrations was not extended. 
This event demonstrated the apparent return of the luteolytic mechanism in mares around 
the described length of average prolonged luteal function. 
This study evaluated the ability of the endometrium in mares in a state of 
prolonged luteal activity to synthesize and secrete PGF2α. The main metabolite of 
PGF2α is 13,14-dihydro-15-keto-prostaglandin F2α (PGFM), which has a longer half-life 
and is representative of circulating concentrations of PGF2α [131]. In the development 
and refinement of estrus suppression therapies, it is important to understand the dynamic 
physiology of the mare endometrium. By analyzing the concentrations of PGFM in 
response to an oxytocin bolus in mares at different time-points of prolonged luteal 
activity, the hypothesized return of the luteolytic pathway can be assessed.  
 
2. Materials and Methods 
2.1 Animal Care and Use 
All animal procedures were approved and conducted following the guidelines of 
the Utah State University Institutional Animal Care and Use Committee (Protocol 
#10079). This study used 14 American Quarter Horse-type mares ranging from 3 to 18 
years of age with known reproductive and health histories. Before inclusion in this study 
each mare was evaluated by transrectal palpation and ultrasonography and determined to 




2.2 Experimental Protocol 
Between May and September in the Northern Hemisphere (41.7° N), cycling 
mares were examined using transrectal palpation and ultrasonography. Mares with an 
ovarian follicle ≥ 30 mm in diameter and prominent endometrial edema were examined 
daily until ovulation (day 0) was detected. Ovulation was defined as the disappearance of 
a follicle > 35 mm in diameter with the resulting CL being observed by transrectal 
ultrasonography. Following ovulation, mares were treated with one of two oxytocin-
based methods of prolonging luteal function. Three mares were treated with 2400 IU of a 
proprietary slow-release oxytocin administered IM on days 7 and 10 after ovulation as 
described by a previous publication [132]. Eight mares were treated from day 7 through 
14 with a single daily injection of 60 IU of aqueous oxytocin IM (Oxytocin, Bimeda-
MTC Animal Health Inc., Cambridge, ON, Canada) following a protocol previously 
described by Vanderwall et al. [10]. Mare serum was evaluated for progesterone 
concentrations to determine prolonged luteal function. After mares were determined to 
have luteal activity for longer than 30 days, they were assigned to groups at 50-59 (50s: n 
= 4), 60-69 (60s: n = 4), and 70-79 (70s: n = 3) days post-ovulation to undergo an 
exogenous “oxytocin challenge.” A control group (n = 3) was untreated and underwent 
the oxytocin challenge at 14 days post-ovulation to replicate an expression of PGFM at a 
physiologically normal time point.  
 
2.3 Blood Collection 
Using red-top blood collection tubes with no anticoagulant, blood samples from 
the jugular vein were collected on day 0 and every Monday, Wednesday, and Friday until 
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one week following the oxytocin challenge date. Red-top blood collection tubes were 
allowed to clot at room temperature before being centrifuged at 125 × g for 20 minutes at 
21° C, after which serum was recovered from each sample and stored at -20° C until it 
was analyzed for progesterone concentration. Jugular blood samples during oxytocin 
challenges were collected in green-top tubes with sodium heparin. Green-top samples 
were immediately placed on ice until centrifuged at 1000 × g for 10 minutes at 5° C. 
Plasma was then recovered from the green-top samples and stored at -20° C until it was 
analyzed for PGFM concentration.  
 
2.4 Oxytocin Challenge 
A single bolus of 10 IU of aqueous oxytocin was given IV at time 0. Blood 
samples were collected 30 and 15 minutes prior to the oxytocin bolus, time 0 was 
collected immediately before oxytocin administration and subsequent sampling at 5, 10, 
15, 20, 25, 30, 45, 60, 75, 90, 105, and 120 minutes after oxytocin administration. All 
mares were evaluated using transrectal ultrasonography immediately before the oxytocin 
challenge began to visually assess CL presence and endometrial edema.  
 
2.5 Hormone Assays 
2.5.1 Progesterone Assay 
Serum samples were processed and evaluated for progesterone concentration 
using a commercially available kit (Immulite Progesterone, Siemens, Malvern, PA, USA) 
according to the manufacturer’s instructions. The sensitivity of this assay was 0.2 ng/mL. 
Intra-assay and inter-assay coefficients of variation were 11.6% and 14.6%, respectively. 
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Mares were considered candidates for the oxytocin challenge only if levels of 
progesterone concentration remained > 1.0 ng/mL until the date of the oxytocin 
challenge.  
 
2.5.2 PGFM Assay 
Plasma samples were evaluated for 13,14-dihydro-15-keto-prostaglandin F2α 
using a commercially available kit (13,14-dihydro-15-keto-prostaglandin F2α Elisa Kit, 
#516671, Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s 
instructions. This assay was previously validated by Keith, et. al. [13]. The sensitivity of 
this assay was 16.3 pg/mL. Intra-assay and inter-assay coefficients of variation were 
14.1% and 17.7%, respectively.  
 
2.6 Statistical Analysis 
PGFM concentrations were compared by evaluating the interaction of the area 
under the curve and the treatment groups using a one-way Analysis of Variance 
(ANOVA) and the Tukey-Kramer method of multiple comparisons. Values of area under 
the curve (AUC) were normalized before evaluation by ANOVA by a Log10 
transformation. The maintenance of luteal function was compared to the PGFM area 
under the curve using an unpaired t-test to provide supporting statistics. All statistical 
analyses were performed using GraphPad Prism (GraphPad Prism version 7.04 for 
Windows, GraphPad Software, La Jolla, California, USA). A P value of P≤0.05 was 





The concentration of PGFM was higher in the 70s group than in the 50s group (p 
< 0.001) and 60s group (p = 0.01) in response to an oxytocin bolus of 10 IU (Fig. 7 and 
Fig. 8). The concentration of PGFM following oxytocin was not significantly different 
comparing the control group to the 70s group (p = 0.36), or between the 50s group to the 
60s group (p = 0.23) (Fig. 8). The concentrations of PGFM among all groups compared 
using an ANOVA model were significantly different (p > 0.006). The maintenance or 
loss of luteal function following the oxytocin challenge was dependent on the 
endometrial response of concentration of PGFM during the oxytocin challenge (p < 
0.001; see Fig. 9 and Fig. 10). Progesterone concentration was maintained above 1 ng/mL 
in 4/4 (100%) of mares in the 50s group, 3/4 (75%) of mares in the 60s group, and 0/3 
(0%) of mares in the 70s group following the oxytocin challenge (Fig. 10). In a 
comparison of the proportion of treated mares with prolonged CL function and mares 
who underwent luteolysis, the abundance of PGFM (AUC) during the oxytocin challenge 
significantly influenced the occurrence of luteolysis (P = 0.023).  The average peak 
concentration of PGFM for the control, 50s, 60s, and 70s groups during the oxytocin 
challenge was 1221 pg/mL, 283 pg/mL, 567 pg/mL, and 1769 pg/mL, respectively.  
 
4. Discussion 
Extending the functional span of the CL has gained increased use as a method of 
estrus suppression in mares. There are many techniques that can be therapeutically 
implemented to achieve this goal including the use of IUDs and oxytocin therapies [1]. 
These clinical tools have an influential effect on the synthetic enzymes for PGF2α,  
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Fig. 7. Plasma concentrations of of 13,14-dihydro-15-keto prostaglandin F2α in mares 
treated at 14 (control), 50-59, 60-69, and 70-79 days post ovulation, with an intravenous 




*Values of area under the curve were normalized by 
logarithmic transformation from the time of 
oxytocin injection (0) until 60 minutes. 
 
Fig. 8. Chart of multiple comparisons of PGFM, made 
by statistical analysis using Tukey Kramer test for 
multiple comparisons from an analysis of variance 
model.  
 
creating a gap in the pathway to trigger luteolysis. The inhibition of COX-2 by using 
oxytocin or certain IUDs has been shown to be an effective method to maintain CL 
function [13,77]. Continued production of progesterone from prolonged luteal activity 
remains above 1 ng/mL until an average of 65 days post-ovulation [15]. The results of 
this study reveal that there is a return of the luteolytic mechanism coinciding with the 
average length of prolonged luteal function.  
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Fig. 9. Serum progesterone concentrations in mares treated with oxytocin 
therapies to prolong CL function. For clarity, lines are truncated after 
physiological determined luteolysis. A threshold for progesterone 




*All mares who underwent luteolysis did so within 48 
hours of oxytocin administration. 
 
Fig. 10. Proportions of mares treated with oxytocin therapies to 
prolong CL function who underwent luteolysis after receiving a 
bolus of 10 IU of oxytocin administered intravenously. 
 
A robust increase in PGFM concentrations in response to an oxytocin bolus 
suggests that; (1) the oxytocin receptor is present and expressed on the endometrium, (2) 
secondary synthetic enzymes (COX-2) are present to produce PGF2α, and (3) PGF2α is 
produced and systemically circulated in great enough quantities to achieve luteolysis. Six 
of seven mares 50-69 days post-ovulation did not show a robust response of PGFM 
concentrations after a bolus of 10 IU of oxytocin. The lack of a PGFM response indicates 
that one or more of the components of the luteolytic process outlined above are not 
present and/or functional at this time. This lack of PGF2α secretion corresponds with 
post-oxytocin progesterone concentrations as all mares 50-59 days, and 3 of 4 mares 60-
69 days post-ovulation maintained progesterone concentrations > 1 ng/mL for one week 
after oxytocin administration. Alternatively, all mares 70-79 days post ovulation showed 
a robust spike in PGFM concentrations in response to a 10 IU oxytocin bolus and failed 
to maintain progesterone concentrations soon after the oxytocin challenge. All mares in 
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this study that underwent luteolysis, following the oxytocin bolus, did so within 48 hours. 
The profile of diminishing progesterone concentrations after the oxytocin challenge is 
similar to other studies regarding luteolysis [53].  
For comparison, the primary CL in pregnant mares stands alone as the main 
ovarian producer of progesterone for about 40 days. At this time, equine chorionic 
gonadotropin (eCG), synthesized by endometrial cups of the placenta, has a luteotrophic 
effect on the ovaries and influences the ovulation and development of secondary and 
accessory corpora lutea [23]. In the non-pregnant mare with prolonged luteal function, 
this study has shown that there is a return of the luteolytic mechanism between 50 and 70 
days after ovulation. Oxytocin therapies to prolong luteal function in non-pregnant mares 
and the establishment of pregnancy share some similarities. In both events, there is an 
inhibition of COX-2 [13,76]. More research is needed to understand how either event 
disrupts the expression of COX-2.  In pregnancy, there is continual stimulus which may 
play a role on the later expression of luteolytic pathway components. The addition of 
supplemental corpora lutea and the feto-placental unit as a source of progestins allows for 
a continual source of progesterone secretion from the time of initial luteinization of the 
primary CL to full term [23]. It has been shown in pregnant mares that there is a PGFM 
response to oxytocin beginning at around day 18 after ovulation [82]. In the normal-
cycling non-pregnant mare, it has been shown that PGFM response induced by oxytocin 
peaks earlier, during the luteolytic time frame [79]. The present study indicates that the 
PGFM response to oxytocin in mares therapeutically treated with described oxytocin 
estrus suppression protocols is delayed until beyond 60 days after ovulation. The first key 
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step to oxytocin stimulated prostaglandin release is the ability of oxytocin to bind to its 
receptor at the endometrium. In mares treated with oxytocin therapies for estrus 
suppression, there is no significant difference in oxytocin binding capacity to its receptor 
and one study has shown that there is an elevated level of oxytocin receptor expression in 
comparison to a control group [10,129]. In pregnant mares, oxytocin receptor expression 
is similar to non-pregnant mares on day 12, but is significantly lower in comparison on 
day 14 post-ovulation [91].  
There are many different techniques exploited for estrus suppression in mares. 
The extension of CL function relies on the interruption of the luteolytic mechanism. In 
efforts to achieve a more clinically applicable method of extending CL function, 
understanding the return of the luteolytic mechanism in a state of prolonged luteal 
activity is very important. Blocking the return of the luteolytic mechanism could allow 
for continued secretion of progesterone beyond the average of 65 days. A longer period 
of prolonged luteal function would be very beneficial in the application of methods of 
estrus suppression. More research to extend prolonged CL function must be done. The 
results of this study help to understand the changes in the uterine environment during the 
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